Pharmaceutical combination of probucol with statin or monascus and use thereof

Abstract

The present invention relates to a pharmaceutical composition for treating hyperlipidemia. In particular, the present invention relates to a pharmaceutical combination of probucol with a statin drug / monascus, a pharmaceutical composition or kit containing probucol and a statin drug / monascus, and use of the pharmaceutical combination or the pharmaceutical composition or kit in preparing a medicament for treating hyperlipidemia, especially severe hypertriglyceridemia, severe hypercholesterolemia, and statin-refractory or statin-resistant hypercholesterolemia. The present invention is characterized in that the pharmaceutical combination or the pharmaceutical composition or kit containing probucol and the statin drug contain reduced doses of probucol and the statin drug / monascus, and the probucol and the statin / monascus are configured for simultaneous administration.

Description

Drug combination of probucol and statins or red yeast rice and application thereof Citation of Related Applications This application claims priority to the following applications, which are incorporated herein in their entirety by reference: Chinese patent application number 202410164131.7, filed on February 5, 2024, and entitled “Drug Combination for Treating Severe Hypertriglyceridemia”, Chinese patent application number 202410164129.X, filed on February 5, 2024, and entitled “Chinese and Western Medicine Combination for Treating Severe Hypertriglyceridemia”, Chinese patent application number 202411662172.5, filed on November 20, 2024, and entitled “ The Chinese patent application for "Drug combination for treating hyperlipidemia" is filed on November 20, 2024, with application number 202411662173.X, application date November 20, 2024, and invention name "Chinese and Western medicine combination for treating hyperlipidemia"; the Chinese patent application for "Drug combination for treating hyperlipidemia" is filed on December 4, 2024, with application number 202411766637.1, application date December 4, 2024, and invention name "Chinese and Western medicine combination for treating hyperlipidemia"; the Chinese patent application for "Drug combination for treating hyperlipidemia" is filed on December 4, 2024, with application number 202411766636.7, application date December 4, 2024, and invention name "Chinese and Western medicine combination for treating hyperlipidemia". Technical Field The present invention relates to a pharmaceutical combination of probucol and a statin or red yeast rice, a pharmaceutical composition comprising probucol and a statin or red yeast rice, and uses of the pharmaceutical combination and the pharmaceutical composition for treating hyperlipidemia, particularly severe hypertriglyceridemia and severe hypercholesterolemia. Background Art Severe hypertriglyceridemia is a specific type of hyperlipidemia. Besides cardiovascular risks, it can also induce pancreatitis. Numerous medications are available for treating hyperlipidemia, but the number of drugs specifically for severe hypertriglyceridemia is relatively limited, with only three oral options: fibrates, high-dose fish oil omega-3, and niacin. In clinical practice, fibrates are the preferred first-line treatment, with fish oil used as an adjunct. They are slow-acting and less effective than fibrates, and niacin is even less effective. Fibrate intolerance is not uncommon, resulting in complications such as myolysis and impaired liver and kidney function. If toxic side effects occur, there are no alternatives, leading to a poor prognosis and a current clinical treatment challenge. Other treatment options include biologics and plasma adsorption, but biologics are difficult to commercialize due to side effects, while plasma adsorption is limited due to its high technical requirements, high cost, and significant side effects. Furthermore, patients with severe hypertriglyceridemia often have concurrent ASCVD risk or hypercholesterolemia, requiring concomitant statin therapy. Combining statins with fibrates can enhance toxicity and side effects. Therefore, there is an urgent clinical need for drugs or drug combinations that can replace fibrates to treat severe hypertriglyceridemia, significantly reduce low-density lipoprotein-C (LDL-C) and cholesterol, and have low side effects and good tolerance. LDL-C is recognized as the most important risk factor for cardiovascular disease. Statins are very effective in controlling low-density cholesterol, but some patients still have poor responses to statins, and the benefits of increasing statins are limited, with increased side effects, requiring combination with other drugs. According to the 2023 Chinese Guidelines for Blood Lipid Management, when LDL-C is not up to standard after statin treatment, consider combining statins with cholesterol absorption inhibitors (such as ezetimibe) and / or PCSK9 inhibitors. Statins combined with ezetimibe can further reduce LDL-C levels by 18-20% (Chinese Guidelines for Blood Lipid Management (2023), Joint Expert Committee for Revision of the Chinese Guidelines for Blood Lipid Management, Chinese Journal of Circulation, March 2023, Vol. 38, No. 3, pp. 237-271). Therefore, there is an urgent clinical need for drugs or drug combinations that can further significantly reduce LDL-C when statins and / or red yeast rice treatment are ineffective or inefficient. Furthermore, some people respond poorly to existing lipid-lowering drugs for both cholesterol and triglyceride levels, requiring a combination of two or more. These drugs are typically used at their original doses, potentially leading to increased toxicity and side effects. Therefore, there is an urgent clinical need for a lipid-lowering drug combination that offers low doses, optimal efficacy, and minimal side effects. Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors, can significantly lower TC and LDL-C, and can also mildly reduce serum triglyceride levels. Statins are indicated for the prevention and treatment of hypercholesterolemia, combined hyperlipidemia, and ASCVD. They are less effective for significant hypertriglyceridemia and chylomicronemia, and are not indicated for the treatment of severe hypertriglyceridemia. Existing statins require different doses to achieve the same lipid-lowering goal. It is important to note that doubling the statin dose only increases the LDL-C reduction by 6% (the so-called "6% statin effect"), as described in the "Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China (2016 Revised Edition)." Achieving target values depends not only on the statin dose but also on the patient's baseline LDL-C level. For example, if the LDL-C level is 188 mg / dL, even with 80 mg / day of atorvastatin, it would be difficult to achieve the target of <70 mg / dL. Moreover, when the dose of statins is doubled, the side effects increase with the dose. Probucol (CAS No.: 23288-49-5) is a bisphenol lipid-lowering compound. Probucol has minimal effect on triglycerides and is only suitable for hypercholesterolemia with high LDL. The usual dosage is 0.5g / time, twice daily (i.e., a daily dose of 1000mg). Literature reports that 1 gram per day can reduce cholesterol by 9-29% and LDL-C by 10-15% (Li Jiatai, ed., Clinical Pharmacology, People's Medical Publishing House, 3rd edition, page 1531). According to the 2023 Chinese Guidelines for Blood Lipid Management, probucol is mainly suitable for patients with familial hypercholesterolemia (FH) and xanthomas. There is no mention of lowering triglycerides, let alone the benefits of combined therapy from lowering triglycerides, especially in severe hypertriglyceridemia, nor is there any mention of the benefits of combining with statins to further lower LDL-C. The combination of statins and probucol is primarily used to treat hypercholesterolemia, but there are no reports of its use in treating severe hypertriglyceridemia. Statins are not ideal for treating severe hypercholesterolemia. Some documents, such as CN106176717A, CN101411703A, CN101766594A, and CN101455842A, disclose compositions containing statins and probucol. However, none of these documents disclose the use of probucol at low doses, nor do they report that the combination of statins and probucol can be used to treat severe hypertriglyceridemia and severe hypercholesterolemia. There are also no reports on how to use probucol to enhance the effect of statins in lowering LDL-C levels to treat hypercholesterolemia. Furthermore, there is no teaching or suggestion that taking statins and probucol separately is ineffective, or that increasing the probucol dose is also ineffective. Chen Sijia et al. (Meta-analysis of probucol combined with statins for the treatment of carotid artery plaques, Chinese Journal of Stroke, Vol. 19, No. 3, March 2024. 299-399) clearly pointed out that probucol combined with statins has no further advantages in lowering LDL-C levels. When statins are ineffective, guidelines and textbooks recommend a variety of combination medications, such as ezetimibe, PCSK9 monoclonal antibodies, fibrates (combining these two medications increases side effects, but is still recommended), niacin, and even the health supplement fish oil. The drug inserts for ezetimibe, PCSK9 monoclonal antibodies, fibrates, niacin, and fish oil also include instructions for combining them with statins. Unfortunately, authoritative guidelines at home and abroad do not recommend combining them with probucol, and the probucol drug insert does not mention combining them with statins. Using the conventional dosage of 0.5g of probucol twice daily, taken at bedtime with statins, the combination of these two cholesterol-lowering drugs has no effect on improving severe triglyceridemia. Joseph L. et al. reported that the combination of lovastatin and probucol was no more effective than lovastatin alone in lowering low-density lipoprotein cholesterol. The drugs used in this paper were: lovastatin 20 mg twice daily; lovastatin 20 mg twice daily combined with probucol 500 mg twice daily (Joseph L. Witztum, MD, et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation Vol 79, No 1, January 1989). The PROSPECTIVE study enrolled 876 ASCVD patients who took statins and other lipid-lowering drugs for more than 8 weeks (statins accounted for 92.7% of the total cases) and were divided into two groups: continuing the original treatment and combining probucol 250 mg BID on the basis of the original treatment. The patients were followed up for more than 3 years. The probucol group had no statistically significant effect in reducing cardiovascular and cerebrovascular events and reducing carotid intima-media thickness, and the results remained negative (Toshiyuki Ishibashi, et al. Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE) J Atheroscler Thromb, 2021; 28: 103-123). These research results have led to guidelines, textbooks, and drug instructions both domestically and internationally not recommending the combination of statins with probucol to further lower LDL-C. For example, the pravastatin instructions state, "Although there was no increase in adverse events with the combination of pravastatin and probucol, no enhancement of LDL-lowering efficacy was observed." Existing technologies offer no significant benefit in either lowering triglycerides or further lowering LDL-C in patients with severe hypertriglyceridemia. Red yeast rice is a traditional Chinese medicine and food with a long history. The lipid-lowering and vascular protective effects of red yeast rice have been recognized. The 2023 Chinese Guidelines for Blood Lipid Management include red yeast rice under the entry of other lipid-regulating drugs that mainly lower cholesterol. The European Guidelines for Blood Lipids list red yeast rice as a dietary supplement for lowering cholesterol. Currently, red yeast rice products can be purchased on the market under the names of red yeast rice (powder / rice), functional red yeast rice (powder / rice), red yeast rice extract, etc. The Chinese patent medicines made using the lipid-lowering effect of red yeast rice mainly include Zhibituo, Zhibitai, Xuezhikang, etc. Although there are reports in the literature on the combined use of Chinese patent medicines such as Zhibitai and probucol (Xue Jing: Clinical study on the treatment of hyperlipidemia with Zhibitai capsules combined with probucol, "Modern Medicine and Clinic", February 2023, Vol. 38, No. 2: 346-349), the disclosed treatment method does not use low-dose probucol, nor does it administer red yeast rice drugs and probucol at the same time, and the indications targeted do not include severe hypertriglyceridemia, etc. involved in the present invention. Summary of the Invention The inventors unexpectedly discovered that a drug combination comprising a low dose of probucol and a statin / red yeast rice can significantly reduce high triglycerides in severe hypertriglyceridemia, with an effect comparable to that of fibrates; it can further reduce cholesterol and low-density lipoprotein, with an effect comparable to that of statins and statins combined with ezetimibe; it can be used to treat (severe) hypertriglyceridemia and / or (severe) hypercholesterolemia, and is a broad-spectrum lipid-lowering drug; while reducing the risk of ASVCD and the side effects of the drug, thereby meeting clinical needs. Surprisingly, if probucol and statins / red yeast rice are taken separately, or if they are taken together but the probucol dose is increased, the unexpected effect disappears. In a first aspect of the present invention, a pharmaceutical combination is provided, comprising probucol and a statin / red yeast rice. In a second aspect of the present invention, a pharmaceutical composition is provided, comprising probucol, a statin / red yeast rice and a pharmaceutically acceptable carrier. In a third aspect of the present invention, a kit is provided, comprising a first composition containing probucol and a second composition containing statins / red yeast rice. In a fourth aspect of the present invention, there is provided use of probucol and statins / red yeast rice in the preparation of a medicament for treating hyperlipidemia. In a fifth aspect of the present invention, a pharmaceutical combination comprising probucol and a statin / red yeast rice or a pharmaceutical composition comprising probucol, a statin / red yeast rice and a pharmaceutically acceptable carrier is provided for use in treating hyperlipidemia. In a sixth aspect of the present invention, a method for treating hyperlipidemia is provided, comprising administering a therapeutically effective amount of probucol and a therapeutically effective amount of a statin / red yeast rice to a subject in need thereof. In the above aspects, the statin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. In the fourth, fifth and sixth aspects, the hyperlipidemia includes (severe) hypertriglyceridemia and / or (severe) hypercholesterolemia. The hyperlipidemia can be familial or non-familial hyperlipidemia, such as familial or non-familial (severe) hypertriglyceridemia and / or familial or non-familial (severe) hypercholesterolemia. Specifically, the present invention provides the following technical solutions: 1. A drug combination, wherein the drug combination is a drug combination comprising probucol and a statin, or a drug combination comprising probucol and red yeast rice; preferably, probucol and the statin or red yeast rice are configured to be administered simultaneously. 2. The drug combination according to technical solution 1, wherein the statin is selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin; Preferably: The weight ratio of probucol to atorvastatin is no greater than 25 / 2, or no greater than 20 / 1, or no greater than 25 / 1, or no greater than 125 / 4, or no greater than 75 / 2, or no greater than 50 / 1, or no greater than 125 / 2, or no greater than 75 / 1; and optionally, the weight ratio of probucol to atorvastatin is no less than 2 / 1, or no less than 5 / 1, or no less than 10 / 1; or The weight ratio of probucol to atorvastatin is (3-25):1; or The weight ratio of probucol to fluvastatin is no greater than 25 / 16, or no greater than 5 / 2, or no greater than 25 / 8, or no greater than 125 / 32, or no greater than 75 / 16, or no greater than 25 / 4, or no greater than 125 / 16, or no greater than 75 / 8, and optionally the weight ratio of probucol to fluvastatin is no less than 1 / 4, or no less than 5 / 8, or no less than 5 / 4; or The weight ratio of probucol to fluvastatin is (1-4):1; or The weight ratio of probucol to lovastatin is no greater than 25 / 4, or no greater than 10 / 1, or no greater than 25 / 2, or no greater than 125 / 8, or no greater than 75 / 4, or no greater than 25 / 1, or no greater than 125 / 4, or no greater than 75 / 2; and optionally, the weight ratio of probucol to lovastatin is no less than 1 / 1, or no less than 5 / 2, or no less than 5 / 1; or The weight ratio of probucol to lovastatin is (3-40):1; or The weight ratio of probucol to pitavastatin is no greater than 125 / 2, or no greater than 100 / 1, or no greater than 125 / 1, or no greater than 625 / 4, or no greater than 375 / 2, or no greater than 250 / 1, or no greater than 625 / 2, or no greater than 375 / 1; and optionally, the weight ratio of probucol to pitavastatin is no less than 10 / 1, or no less than 25 / 1, or no less than 50 / 1; or The weight ratio of probucol to pitavastatin is (80-150):1; or The weight ratio of probucol to pravastatin is no greater than 25 / 8, or no greater than 5 / 1, or no greater than 25 / 4, or no greater than 125 / 16, or no greater than 25 / 3, or no greater than 75 / 8, or no greater than 25 / 2, or no greater than 125 / 8, or no greater than 75 / 4; and optionally, the weight ratio of probucol to pravastatin is no less than 1 / 2, or no less than 5 / 4, or no less than 5 / 2; or The weight ratio of probucol to pravastatin is (6-10):1; The weight ratio of probucol to rosuvastatin is no greater than 25 / 2, or no greater than 20 / 1, or no greater than 25 / 1, or no greater than 125 / 4, or no greater than 75 / 2, or no greater than 50 / 1, or no greater than 125 / 2, or no greater than 75 / 1; and optionally, the weight ratio of probucol to rosuvastatin is no less than 2 / 1, or no less than 5 / 1, or no less than 10 / 1; or The weight ratio of probucol to rosuvastatin is (5-60):1; or The weight ratio of probucol to simvastatin is no greater than 25 / 4, or no greater than 10 / 1, or no greater than 25 / 2, or no greater than 125 / 8, or no greater than 75 / 4, or no greater than 25 / 1, or no greater than 125 / 4, or no greater than 75 / 2; and optionally, the weight ratio of probucol to simvastatin is no less than 1 / 1, or no less than 5 / 2, or no less than 5 / 1; or The weight ratio of probucol to simvastatin is (1-15):1. 3. The drug combination according to any one of technical solutions 1-2, wherein the drug combination comprises 20-400 mg of probucol and 0.5-80 mg or 1-80 mg of a statin, For example: 5-80 mg, or 10-80 mg, or 5-40 mg, or 10-20 mg, or 10-40 mg of atorvastatin; or 10-80 mg, or 20-80 mg, or 40-80 mg of fluvastatin; or 5-80 mg, or 10-80 mg, or 10-40 mg, or 20-40 mg, or 10-20 mg of lovastatin; or 0.5-4 mg, or 1-4 mg, or 2-4 mg, or 2-3 mg of pitavastatin; or 5-80 mg, or 10-80 mg, or 20-80 mg, or 20-40 mg, or 10-40 mg, or 10-20 mg of pravastatin; or 2.5-40 mg, or 5-40 mg, or 10-40 mg, or 2.5-20 mg, or 5-10 mg, or 5-20 mg of rosuvastatin; or 5-80 mg, or 20-80 mg, or 5-40 mg, or 20-40 mg, or 10-40 mg of simvastatin; Optionally, the drug combination does not include the following combinations 1-69: 4. The pharmaceutical combination according to any one of technical solutions 1 to 3, wherein the amount of probucol as the active ingredient is 20 mg, 25 mg, 30 mg, 31.25 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 62.5 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 187.5 mg, 190 mg, 19 5mg, 200mg, 205mg, 210mg, 215mg, 220mg, 225mg, 230mg, 235mg, 240mg, 245mg, 250mg, 255mg, 260mg, 265mg, 270mg, 275mg, 280mg, 285mg, 290mg, 295mg, 300mg, 305mg, 310mg, 312.5mg, 315mg, 320mg, 325mg, 330mg, 335mg, 340mg, 345mg, 350mg, 355mg, 360mg, 365mg, 370mg, 375mg, 380mg, 385mg, 390mg, 395mg, or 400mg; or The amount of probucol as the active ingredient is 20-400 mg, excluding 20 mg, 25 mg, 30 mg, 31.25 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 62.5 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 187.5 mg, 190 mg, 195 mg, 2 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg and / or 400 mg. 5. The drug combination according to technical solution 1, wherein the drug combination comprises 20-400 mg of probucol and 2-50 mg (e.g., 3-40 mg, 5-35 mg, 7-30 mg, or 7-20 mg, such as 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 7.5 mg, 8 mg, 8.3 mg, 9 mg, 10 mg, 10.5 mg, 11 mg, 12 mg, 12.5 mg, 13 mg, 14 mg, 15 mg, 16 mg, 16.6 mg, 17 mg, 18 mg g, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 24.9mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 33.2mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg or 50mg of red yeast rice (the weight of the red yeast rice is calculated as the active substance monacolin K). 6. The drug combination according to technical solution 1 or 5, wherein the drug combination comprises probucol and red yeast rice, The weight ratio of probucol to red yeast rice is (1-100):1, the weight of the red yeast rice being calculated based on the active substance monacolin K; and / or The weight ratio of probucol to the total amount of monacolin compounds in red yeast rice is (0.8-57):1, and the total amount of monacolin compounds is calculated based on the total amount of monacolin K, monacolin L and / or dehydrated lovastatin. 7. The drug combination according to technical solution 1, 5 or 6, wherein the drug combination comprises probucol and red yeast rice, wherein Red yeast rice is provided in one or more of the following forms: natural red yeast rice, traditional Chinese medicine red yeast rice, functional red yeast rice, red yeast rice extract, and a composition containing red yeast rice; Preferably, the red yeast rice comprises monacolin compounds, wherein the monacolin compounds comprise monacolin K, and optionally, monacolin L and dehydrated lovastatin; More preferably, the red yeast rice extract or the composition containing red yeast rice is selected from Zhibituo, Zhibitai or Xuezhikang; or More preferably, the composition containing red yeast rice contains closed-ring monacolin K and open-ring monacolin K, the total content of the two is 0.2-5wt%, for example, based on the weight of the composition being 100wt%, and the weight ratio of closed-ring monacolin K to open-ring monacolin K is (100:1) to (1:100). 8. The drug combination according to any one of technical solutions 1 and 5-7, wherein the drug combination comprises probucol and red yeast rice, The red yeast rice is provided in the form of a composition containing red yeast rice, which comprises active ingredients and pharmaceutical excipients. The red yeast rice composition contains closed-ring monacolin K and open-ring monacolin K, the total content of the closed-ring monacolin K and the open-ring monacolin K being 0.2-5 wt%, based on 100 wt% of the weight of the composition, and the weight ratio of the closed-ring monacolin K to the open-ring monacolin K being (100:1) to (1:100); Preferably, in the composition containing red yeast rice, the weight ratio of the active ingredient to the pharmaceutical excipient is (5-95):(95-5); the active ingredient includes the traditional Chinese medicine red yeast rice, functional red yeast rice or its extract, and optionally any one or more of hawthorn or its extract, Atractylodes or its extract and Alisma or its extract. 9. The drug combination according to any one of technical solutions 1-8, wherein the drug combination does not include other active ingredients except probucol and statins / red yeast rice. 10. The drug combination according to any one of technical solutions 1 to 9, characterized in that the form capable of simultaneous administration is in the form of an oral unit dosage form selected from tablets, capsules, granules, dripping pills, and micropills, and the oral unit dosage form contains probucol and a statin, or probucol and red yeast rice. 11. The drug combination of technical solution 10 is characterized in that the oral unit dosage form such as a tablet is a two-layer or multi-layer oral unit dosage form such as a two-layer or multi-layer tablet, wherein at least one layer contains probucol and a pharmaceutically acceptable carrier thereof, and at least another layer contains a statin or red yeast rice and a pharmaceutically acceptable carrier thereof. 12. The drug combination described in any one of technical solutions 1-11, which is used to treat hyperlipidemia, treat / prevent atherosclerotic vascular lesions, reduce ischemic stroke, reduce lower limb arteriosclerosis occlusion, reduce ischemic kidney lesions, or reduce cardiovascular events in subjects in need thereof; preferably, probucol and statins or red yeast rice in the drug combination are administered simultaneously. 13. A method for treating hyperlipidemia, treating / preventing atherosclerotic vascular lesions, reducing ischemic stroke, reducing lower limb arteriosclerosis occlusion, reducing ischemic kidney lesions, or reducing cardiovascular events in a subject in need thereof, the method comprising administering an effective amount of the drug combination described in any one of technical solutions 1-11; preferably, probucol and statins or red yeast rice in the drug combination are administered simultaneously. 14. A pharmaceutical composition for treating hyperlipidemia, treating / preventing atherosclerotic vascular lesions, reducing ischemic stroke, reducing lower limb arteriosclerosis occlusion, reducing ischemic kidney disease, or reducing cardiovascular events, the pharmaceutical composition comprising an effective amount of the drug combination described in any one of technical solutions 1-11, and a pharmaceutically acceptable carrier; preferably, probucol and a statin or red yeast rice in the drug combination are administered simultaneously. 15. Use of the drug combination described in any one of technical solutions 1-11 in the preparation of a drug for treating hyperlipidemia, treating / preventing atherosclerotic vascular lesions, reducing ischemic stroke, reducing lower limb arteriosclerosis occlusion, reducing ischemic kidney lesions, or reducing cardiovascular events; preferably, probucol and statins or red yeast rice in the drug combination are administered simultaneously. 16. The pharmaceutical combination according to Technical Solution 12, the method according to Technical Solution 13, the pharmaceutical composition according to Technical Solution 14 or the use according to Technical Solution 15, characterized in that The amount of probucol (in daily dose) is a / 2b, or 3a / 4b, or 5a / 16b of the maximum daily dose of probucol for cholesterol lowering recommended in the "Guidelines for Chinese Blood Lipid Management (2023)", wherein a and b are integers from 1 to 16, and a≤b; for example, the therapeutically effective amount of probucol is 20-800 mg per day, preferably 20 mg-400 mg; Optionally, when the drug combination is a drug combination comprising probucol and a statin, the amount of the statin (in daily dose) is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein c and d are integers of 1-16, and c≤d, for example, c≤d / 2; The maximum daily dose of probucol for lowering cholesterol is 1000 mg; and the maximum daily doses of statins for lowering cholesterol are: lovastatin: 40 mg, pravastatin: 40 mg, simvastatin: 40 mg, fluvastatin: 80 mg, atorvastatin: 80 mg, rosuvastatin: 20 mg, and pitavastatin: 4 mg. Optionally, when the pharmaceutical combination is a pharmaceutical combination comprising probucol and red yeast rice, the amount of red yeast rice (in daily dose) is 2-100 mg, preferably 3-40 mg, 5-35 mg, 7-30 mg, or 7-20 mg, calculated as the active substance monacolin K; or: The therapeutically effective amount of probucol can be 20 mg, 25 mg, 30 mg, 31.25 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 62.5 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 15 5mg, 160mg, 165mg, 170mg, 175mg, 180mg, 185mg, 187.5mg, 190mg, 195mg, 200mg, 205mg, 210mg, 215mg, 220mg , 225mg, 230mg, 235mg, 240mg, 245mg, 250mg, 255mg, 260mg, 265mg, 270mg, 275mg, 280mg, 285mg, 290mg, 295mg , 300mg, 305mg, 310mg, 312.5mg, 315mg, 320mg, 325mg, 330mg, 335mg, 340mg, 345mg, 350mg, 355mg, 360mg, 365mg, 370mg, 375mg, 380mg, 385mg, 390mg, 395mg or 400mg; or a combination of any two of these point values such as 62.5mg-125mg, or 62.5mg-187.5mg, or 62.5mg-250mg, or 62.5mg-312.5mg, or 62.5mg-375mg, or 125mg-187.5mg, or 125mg-250mg, or 125mg-312.5mg, or 125mg-375mg, or 187.5mg-250mg, or 187.5mg-312.5mg, or 187.5mg-375mg, or 250mg-312.5mg, or 250mg-375mg, or 312.5mg-375mg, or 50mg-100mg, or 50mg-150mg, or 50mg-200mg, or 50mg-250mg, or 50mg-300mg, or 50mg-350mg, or 50mg-400mg, or 100mg-150mg, or 100mg-200mg, or 100mg-250mg, or 100mg-300mg, or 100mg-350mg, or 100mg-400mg, or 150mg-200mg, or 150mg-250mg, or 150mg g-300mg, or 150mg-350mg, or 150mg-400mg, or 200mg-250mg, or 200mg-300mg, or 200mg-350mg, or 200mg-400mg, or 250mg-300mg, or 250mg-350mg, or 250mg-400mg, or 300mg-300mg, or 300mg-350mg, or 300mg-400mg, or 350mg-350mg, or 350mg-400mg, or 400mg-400mg;. Optionally, when the drug combination is a drug combination comprising probucol and a statin, the therapeutically effective amount of the statin may be daily: 5-80 mg, or 10-80 mg, or 5-40 mg, or 10-20 mg, or 10-40 mg of atorvastatin; or 10-80 mg, or 20-80 mg, or 40-80 mg of fluvastatin; or 5-80 mg, or 10-80 mg, or 10-40 mg, or 20-40 mg, or 10-20 mg of lovastatin; or 0.5-4 mg, or 1-4 mg, or 2-4 mg, or 2-3 mg of pitavastatin; or 5-80 mg, or 10-80 mg, or 20-80 mg, or 20-40 mg, or 10-40 mg, or 10-20 mg of pravastatin; or 2.5-40 mg, or 5-40 mg, or 10-40 mg, or 2.5-20 mg, or 5-10 mg, or 5-20 mg of rosuvastatin; or 5-80 mg, or 20-80 mg, or 5-40 mg, or 20-40 mg, or 10-40 mg of simvastatin; Optionally, when the pharmaceutical combination is a pharmaceutical combination comprising probucol and red yeast rice, the amount of red yeast rice (in daily dose) is 2-100 mg, preferably 3-40 mg, 5-35 mg, 7-30 mg, or 7-20 mg, calculated as the active substance monacolin K. 17. The pharmaceutical combination according to Technical Solution 12, the method according to Technical Solution 13, the pharmaceutical composition according to Technical Solution 14, or the use according to Technical Solution 15, characterized in that the hyperlipidemia meets one of the following requirements (a)-(e): (a) the subject's TG ≥ 5.6 mmol / L, and / or LDL-C > 4.9 mmol / L; (b) the subject's TC>6.22mmol / L, and / or LDL-C>4.14mmol / L, and / or TG>1.7mmol / L; (c) The subject is a patient at very high risk for ASCVD and meets one of the following conditions: (c.1) LDL-C level greater than 1.8 mmol / L; (c.2) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and the LDL-C level is greater than 1.8 mmol / L; (c.3) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and The subject's LDL-C reduction after treatment is less than 50% compared to baseline; or the subject has severe side effects from statins and needs to reduce the dose; or the subject has severe side effects from cholesterol absorption inhibitors and / or PCSK9 monoclonal antibodies and needs to stop taking statins or red yeast rice in combination with cholesterol absorption inhibitors or statins or red yeast rice in combination with PCSK9 monoclonal antibodies, or statins or red yeast rice in combination with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies; (d) The subject is an ASCVD ultra-high-risk patient and meets one of the following requirements: (d.1) LDL-C level greater than 1.4 mmol / L; (d.2) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and the LDL-C level is greater than 1.4 mmol / L; (d.3) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and The subject's LDL-C level after treatment is reduced by <50% compared to baseline; or Patients who have significant side effects from statins or red yeast rice and need to reduce their dosage; or Patients who have severe side effects from cholesterol absorption inhibitors and / or PCSK9 monoclonal antibodies and need to stop taking statins or red yeast rice in combination with cholesterol absorption inhibitors, or statins or red yeast rice in combination with PCSK9 monoclonal antibodies, or statins or red yeast rice in combination with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies; (e) The subject is a high-risk ASCVD patient and meets one of the following requirements: (e.1) LDL-C level greater than 2.6 mmol / L; (e.2) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and the LDL-C level is greater than 2.6 mmol / L; (e.3) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and The subject's LDL-C level after treatment is reduced by <50% compared to baseline; or Patients who have significant side effects from statins or red yeast rice and need to reduce their dosage; or Patients who have severe side effects from cholesterol absorption inhibitors and / or PCSK9 monoclonal antibodies and need to stop taking statins or red yeast rice in combination with cholesterol absorption inhibitors, or statins or red yeast rice in combination with PCSK9 monoclonal antibodies, or statins or red yeast rice in combination with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies; The ASCVD extremely high-risk patients, ASCVD ultra-high-risk patients, and ASCVD high-risk patients mentioned therein are divided according to the standards of the "Guidelines for Blood Lipid Management in China (2023)". 18. The drug combination according to technical solution 12, the method according to technical solution 13, the pharmaceutical composition according to technical solution 14 or the use according to technical solution 15, characterized in that the hyperlipidemia is Primary hypercholesterolemia, or (Severe) hypertriglyceridemia, or (Severe) hypercholesterolemia, or A combination of (severe) hypertriglyceridemia and (severe) hypercholesterolemia, or Familial or non-familial (severe) hypertriglyceridemia, or Familial or non-familial (severe) hypercholesterolemia, or A combination of familial or non-familial (severe) hypertriglyceridemia and familial or non-familial (severe) hypercholesterolemia, or Hyperlipidemia that is ineffective or ineffective with statins and / or red yeast rice, or (Severe) hypercholesterolemia that is ineffective or ineffective with statins and / or red yeast rice, or (Severe) hypertriglyceridemia that is ineffective or ineffective with statins and / or red yeast rice, or Hyperlipidemia that is intolerant or unresponsive to fibrates, or (Severe) hypertriglyceridemia intolerant of or unresponsive to fibrates. 19. The pharmaceutical combination according to Technical Solution 12, the method according to Technical Solution 13, the pharmaceutical composition according to Technical Solution 14 or the use according to Technical Solution 15, characterized in that: The therapeutically effective amount of probucol can be 62.5 mg-125 mg, or 62.5 mg-187.5 mg, or 62.5 mg-250 mg, or 62.5 mg-312.5 mg, or 62.5 mg-375 mg, or 50 mg-100 mg, or 50 mg-150 mg, or 50 mg-200 mg, or 50 mg-250 mg, or 50 mg-300 mg, or 50 mg-350 mg, or 50 mg-400 mg per day; When the drug combination is a drug combination comprising probucol and a statin, the therapeutically effective amount of the statin may be: 10-20 mg atorvastatin, 5-10 mg rosuvastatin, 20-40 mg fluvastatin, 5-10 mg simvastatin, 10-20 mg lovastatin, 10-20 mg pravastatin, 0.5-1 mg pitavastatin per day; preferably, 10-20 mg atorvastatin / day; or 5-10 mg rosuvastatin / day; or 10 mg simvastatin / day; or 20 mg fluvastatin / day; or 1 mg pitavastatin / day; Preferably, the drug combination is administered once a day, more preferably, before bedtime; Preferably, the hyperlipidemia is primary hypercholesterolemia. 20. A medicine kit, characterized in that the medicine kit contains the drug combination according to any one of technical solutions 1-11, the amount of probucol and the amount of statin / red yeast rice contained in the medicine kit are as described in technical solutions 1-11, and probucol and statin / red yeast rice are provided in the form of a single composition in the medicine kit. 21. A medicine box, characterized in that the medicine box contains the drug combination according to any one of technical solutions 1-11, The medicine kit comprises a first pharmaceutical composition containing probucol and a second pharmaceutical composition containing statins / red yeast rice, The first pharmaceutical composition and the second pharmaceutical composition are configured to be administered simultaneously, The amount of probucol in the first pharmaceutical composition and the amount of statin / red yeast rice in the second pharmaceutical composition are as described in technical solutions 1-11, The first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form. Preferably, the first pharmaceutical composition and the second pharmaceutical composition are provided in separate dosage forms. More preferably, the separate dosage forms are independently selected from tablets, capsules, granules, pills, and micropills. Alternatively, preferably, the first pharmaceutical composition and the second pharmaceutical composition are provided in a single dosage form. More preferably, the single dosage form is selected from tablets, capsules, granules, pills, and micropills. Further more preferably, the single dosage form such as a tablet is a two-layer or multi-layer oral unit dosage form such as a two-layer or multi-layer tablet, wherein at least one layer contains probucol and a pharmaceutically acceptable carrier thereof, and at least another layer contains red yeast rice and a pharmaceutically acceptable carrier thereof. 22. A medicine box, characterized in that the medicine box contains the drug combination according to any one of technical solutions 1-11, The medicine kit comprises one or more identical medicine units isolated from the external environment, each medicine unit comprising a first medicine composition containing probucol and a second medicine composition containing a statin / red yeast rice. The amount of probucol in the first pharmaceutical composition and the amount of statin / red yeast rice in the second pharmaceutical composition are as described in technical solutions 1-11, The first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form (i.e., the first pharmaceutical composition and the second pharmaceutical composition are provided in separate unit dosage forms, preferably, the separate unit dosage forms are independently selected from tablets, capsules, granules, pellets, micropills), Opening of each pharmaceutical unit exposes the first pharmaceutical composition and the second pharmaceutical composition to the external environment simultaneously. 23. The medicine box according to technical solution 21 is characterized in that the medicine box includes one or more identical drug units isolated from the external environment. One, two or three, preferably one or two drug units, can be opened simultaneously each time the drug is administered. Each drug unit contains probucol and statins / red yeast rice as active ingredients. Opening each drug unit can expose probucol and statins / red yeast rice to the external environment at the same time. DETAILED DESCRIPTION Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term "combination" refers to two or more drugs that are administered simultaneously, separately, or sequentially. In some embodiments, "combination" refers to simultaneous administration, for example, the two drugs are administered in a single dosage form. In other embodiments, "combination" refers to separate administration, for example, the two drugs are administered in separate dosage forms but are administered substantially simultaneously, for example, with administration intervals of less than 30 minutes. The term "effective amount" or "therapeutically effective amount" as used herein refers to the amount of a compound or combination of compounds that provides an expected clinical or therapeutic benefit in the subject being treated. The therapeutically effective amount will depend on factors such as the general condition (e.g., weight, age and sex) of the subject being treated, the severity of the disease, the specific compound being administered, the dosage regimen, the use of concomitant medications, and can be determined by the prescribing physician according to conventional practice. In this article, unless otherwise indicated, the effective amount, therapeutically effective amount and content of probucol are all based on probucol free phenol, and the effective amount, therapeutically effective amount and content of statins are all based on statins in non-salt form. In this article, in the absence of a prescribed frequency of administration, the term "effective amount" or "therapeutically effective amount" is based on daily. The term "small dose / low dose" used herein refers to a daily dose of probucol that is less than the commonly used daily dose of 1000 mg / day, see the "Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China (2016 Revised Edition)", for example, the daily dose is not more than 800 mg / day, preferably not more than 400 mg / day. As used herein, the term "about" can allow for a degree of variability in a value or range, for example, within ±10%, within ±5%, or within ±1% of a stated value or a stated limit of a range. As used herein, the term "treat" refers to at least partially alleviating, controlling and / or ameliorating a disease or its symptoms. As used herein, the term "subject" refers to a human subject to whom administration of the pharmaceutical combination or pharmaceutical composition of the present invention is intended. The term "QD" as used herein means once daily. As used herein, the term "BID" means twice daily. The term "pharmaceutically acceptable" as used herein refers to those substances or materials that are, within the scope of sound medical judgment, suitable for contact with subjects, such as human tissues, without causing excessive toxicity, irritation, allergic response or other problems, and with a commensurate benefit / risk ratio. The term "pharmaceutically acceptable salt" as used herein refers to an addition salt formed with a pharmaceutically acceptable acid or base, including, for example, hydrochloride, acetate, hydrobromide, sulfate, bisulfate, carbonate, bicarbonate, sulfite, phosphate, hydrogen phosphate, oxalate, malonate, valerate, borate, p-toluenesulfonate, methanesulfonate, tartrate, benzoate, lactate, citrate, maleate, fumarate, malate, salicylate, mandelate, succinate, gluconate, lactobionate, alkali metal salts (e.g., lithium, sodium, potassium, rubidium, cesium salts), alkaline earth metal salts (e.g., magnesium, calcium, strontium, barium salts), aluminum salts, etc. The salts can be prepared by methods well known to those skilled in the art. As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier (or excipient) that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. Any commonly used pharmaceutically acceptable carrier may be used, the selection of which depends on factors such as the specific mode of administration, the effect of the carrier on solubility and stability, and the nature of the dosage form and is within the ordinary skill of those skilled in the art. Examples of pharmaceutically acceptable carriers include, but are not limited to, fillers such as lactose, sucrose, mannitol or sorbitol, cellulose derivatives and / or calcium phosphate; binders such as corn, wheat or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and / or polyvinyl pyrrolidone; disintegrants such as starch, carboxymethyl starch, cross-linked polyvinyl pyrrolidone, alginic acid or its salts; lubricants such as silicic acid, talc, stearic acid or its salts, and / or polyethylene glycol or its derivatives. The term "hyperlipidemia" as used herein refers to abnormal blood lipids with elevated levels of total cholesterol (TC) and / or triglyceride (TG) in serum. The term "hypercholesterolemia" used herein refers to hyperlipidemia with TC>6.22mmol / L or 240mg / dL and / or LDL-C>4.14mmol / L or 160mg / dL, including familial (severe) hypercholesterolemia. The term "severe hypercholesterolemia" as used herein refers to hyperlipidemia with LDL-C>4.9 mmol / L. The term "hypertriglyceridemia" as used herein refers to hyperlipidemia with TG>1.7 mmol / L or>150 mg / dL. The term "severe hypertriglyceridemia" as used herein refers to hyperlipidemia with TG ≥ 5.6 mmol / L (500 mg / dL). The term "fibrate-intolerant or -unresponsive hyperlipidemia" as used herein refers to hyperlipidemia caused by fibrate treatment, liver and kidney damage, elevated muscle enzymes, or TG still greater than 5.6 mmol / L after fibrate treatment. The term "hyperlipidemia that is ineffective or ineffective in treatment with statins and / or red yeast rice" used in this article refers to hyperlipidemia that does not reach the target value recommended by the "Guidelines for Blood Lipid Management in China (2023)" after treatment with statins and / or red yeast rice. Hypercholesterolemia, severe hypercholesterolemia, hypertriglyceridemia, severe hypertriglyceridemia, fibrate-intolerant or non-responsive hyperlipidemia, and hyperlipidemia that is ineffective or ineffective with statins and / or red yeast rice are defined as above. Similar definitions can be used for the following terms: combination of hypertriglyceridemia and hypercholesterolemia, hypercholesterolemia that is ineffective or ineffective with statins and / or red yeast rice treatment, hypertriglyceridemia that is ineffective or ineffective with statins and / or red yeast rice treatment, hypertriglyceridemia that is intolerant or unresponsive to fibrates, combination of severe hypertriglyceridemia and hypercholesterolemia, combination of hypertriglyceridemia and severe hypercholesterolemia, combination of severe hypertriglyceridemia and severe hypercholesterolemia, severe hypertriglyceridemia that is ineffective or ineffective with statins and / or red yeast rice treatment, severe hypertriglyceridemia that is intolerant or unresponsive to fibrates, severe hypercholesterolemia that is ineffective or ineffective with statins and / or red yeast rice treatment. The "probucol" mentioned herein includes probucol and pharmaceutically acceptable salts or esters thereof, such as probucol disuccinate. Herein, unless otherwise specified, the effective amount, therapeutically effective amount and content of probucol or its pharmaceutically acceptable salt or ester are all calculated based on probucol free phenol. The "statins" mentioned herein include statins and pharmaceutically acceptable salts thereof, such as sodium salts, calcium salts, etc. As used herein, the brackets around the term "(severe)" mean that "severe" is optional, so that, for example, the term "(severe) hypertriglyceridemia" refers to hypertriglyceridemia or severe hypertriglyceridemia; the term "(severe) hypercholesterolemia" refers to hypercholesterolemia or severe hypercholesterolemia. The "form capable of simultaneous administration" in the "form capable of simultaneous administration" described herein includes but is not limited to the following: (1) In the form of an oral unit dosage form of tablets, capsules, granules, dripping pills, or micropills, the oral unit dosage form comprising probucol and a statin, or probucol and red yeast rice; for example, the oral unit dosage form, such as a tablet, is a two-layer or multi-layer oral unit dosage form, such as a two-layer or multi-layer tablet, wherein at least one layer comprises probucol and a pharmaceutically acceptable carrier thereof, and at least another layer comprises a statin or red yeast rice and a pharmaceutically acceptable carrier thereof; (2) A kit comprising the pharmaceutical combination of the present invention, wherein the amount of probucol and the amount of statin / red yeast rice contained in the kit are as described herein, and the probucol and statin / red yeast rice are provided as a single composition in the kit; for example, probucol pellets are added to red yeast rice powder in a prescribed amount; (3) A drug kit comprising the drug combination of the present invention, comprising a first pharmaceutical composition containing probucol and a second pharmaceutical composition containing statins / red yeast rice, wherein the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, preferably, the first pharmaceutical composition and the second pharmaceutical composition are provided in separate dosage forms, more preferably, the separate dosage forms are independently selected from tablets, capsules, granules, dripping pills, and micropills; or preferably, the first pharmaceutical composition and the second pharmaceutical composition are provided in a single dosage form, more preferably, the single dosage form is provided in tablets, capsules, granules, dripping pills, and micropills; for example, the single dosage form such as a tablet is a two-layer or multi-layer oral unit dosage form such as a two-layer or multi-layer tablet, wherein at least one layer contains probucol and a pharmaceutically acceptable carrier thereof, and at least another layer contains red yeast rice and a pharmaceutically acceptable carrier thereof; for another example, probucol is made into micropills of a first color, and the statin / red yeast rice is made into micropills of a second color, the two colors may be the same or different, and the two micropills are mixed in the amounts specified herein and made into capsules; (4) A drug box having the drug combination of the present invention, the drug box comprising one or more identical drug units isolated from the external environment, each drug unit comprising a first drug composition comprising probucol and a second drug composition comprising a statin / red yeast rice, the first drug composition and the second drug composition being each an oral unit dosage form (i.e., the first drug composition and the second drug composition are provided in separate unit dosage forms, preferably, the separate unit dosage forms are independently selected from tablets, capsules, granules, dripping pills, micropills), wherein opening of each drug unit allows the first drug composition and the second drug composition to be exposed to the external environment at the same time; for example, one, two or three, preferably one or two drug units can be opened simultaneously for each administration, each drug unit comprising probucol and a statin / red yeast rice as active ingredients, and opening of each drug unit allows probucol and the statin / red yeast rice to be exposed to the external environment at the same time; for example, probucol is made into a tablet of a first color, and the statin / red yeast rice is made into a tablet of a second color, the two colors can be the same or different, and the two tablets are placed in each drug unit in the quantity specified herein. The "red yeast rice" described herein can be provided by natural red yeast rice, traditional Chinese medicine red yeast rice, functional red yeast rice, red yeast rice extract or a composition containing red yeast rice. Natural red yeast rice refers to a product formed naturally by fermenting rice (or crushed rice) with the fungus Monascus sp. Depending on the type of Monascus used, natural red yeast rice can be further categorized as red yeast rice pigment, functional red yeast rice, and brewing red yeast rice. Monascus that can be used include, but are not limited to, Monascus albidulus, Monascus anka, Monascus argentinensis, Monascus aurantiacus, Monascus barkeri, Monascus eremophilus, Monascus floridanus, Monascus fuliginosus, Monascus fumeus, Monascus kaoliang, Monascus lunisporas, Monascus pallens, Monascus paxii, Monascus pilosus, Monascus purpureus, Monascus ruber, Monascus rust rubiginosus), Monascus rutilus, Monascus sanguineus, Monascus pubigerus, and Monascus sp. A commercially available natural red yeast rice or red yeast rice powder containing ≥0.2 wt% of moracolin K on an absolute dry basis. Red yeast rice (Red Yeast Rice) refers to a Chinese medicinal product or intermediate made by processing the mycelium of the Aspergillus fungus, such as Monascus purpureus Went., on rice or japonica rice using traditional Chinese medicine processing methods, such as rinsing. In one embodiment, the Red Yeast Rice contains 3-6 mg / g of unsaturated fatty acids and 15-30 mg / g of lovastatin, with the percentage of open-ring lovastatin in the total lovastatin being 10-90%. Functional red yeast rice refers to a product containing bioactive substances such as monacolin K, which is fermented with rice (or crushed) as the main raw material by Monascus sp. and is divided into red yeast rice and red yeast powder according to its form. In particular, the functional red yeast rice contains ≥0.4wt% of monacolin K on an absolute dry basis [refer to QB / T 2847-2023 Functional red yeast rice (powder)]. The Monascus sp. used to prepare functional red yeast rice may include but is not limited to Monascus albidulus, Monascus fuliginosus, Monascus paxii, Monascus pilosus, Monascus purpureus, and Monascus ruber; in particular, the Monascus is a strain numbered Monascus purpureus or strain number Red Monascus (Monascus ruber). Red yeast rice extract refers to the product obtained in the process of extracting active substances from natural red yeast rice or functional red yeast rice. The specific extraction method is known, for example, reference can be made to the methods disclosed in the literature such as CN1618441A (Di'ao), CN103417601A (Weixin), CN103372040A (Weixin), and CN1174037A (Weixin). Red yeast rice extract can be prepared by those skilled in the art using conventional extraction methods, for example, by refluxing red yeast rice with 50-90% methanol, ethanol or ethyl acetate for 2-3 times, and combining the extracts. The extract can also be post-treated. The post-treatment method is well known to those of ordinary skill in the pharmaceutical field, for example, including filtering and recovering the solvent, concentrating, and drying (such as spray drying) to obtain the final red yeast rice extract. Natural red yeast rice, Chinese herbal red yeast rice, functional red yeast rice and red yeast rice extracts are all commercially available.

[2010] 2) stipulates that for health foods, "the recommended daily intake of red yeast rice is tentatively set at no more than 2g. The lovastatin in the product should be derived from red yeast rice, and the total recommended daily intake of lovastatin is tentatively set at no more than 10mg. If the above limit is exceeded, sufficient evidence of food safety should be provided." The "Red Yeast Health Food Specification Standard" issued by the Health and Welfare Administration of Taiwan Province stipulates that for red yeast rice products, the product specifications and ingredients must meet the requirement of "the daily intake of monacolin K should be at least 4.8mg, but not more than 15mg." The composition containing red yeast rice is a composition containing an active ingredient and a pharmaceutical excipient, wherein the active ingredient includes red yeast rice, functional red yeast rice, or a red yeast rice extract. The composition containing red yeast rice contains closed-ring monacolin K and open-ring monacolin K, the total content of which is 0.2-5wt%, based on 100wt% of the weight of the composition, and the weight ratio of closed-ring monacolin K to open-ring monacolin K can be (100:1) to (1:100), for example, (50:1) to (1:50), or (15:1) to (1:15), or (1:1) to (1:15). In the composition containing red yeast rice, the weight ratio of the active ingredient to the pharmaceutical excipient can be (5-95):(95-5), or (10-90):(90-10), or (20-80):(80-20), or (30-70):(70-30), or (40-60):(60-40), or (45-55):(55-45). The pharmaceutical excipients are conventional and are not particularly limited in the present invention. For example, the pharmaceutical excipients may be selected from disintegrants (selected from one or more of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose), fillers (selected from one or more of lactose, microcrystalline cellulose, sucrose, sorbitol, mannitol, pregelatinized starch, starch), binders (selected from one or more of ethanol, water, ethanol-water solution, syrup, starch slurry, sodium carboxymethyl cellulose solution, polyvinylpyrrolidone solution, or a mixture thereof), flavoring agents (selected from one or more of The pharmaceutical excipients may further include one or more of the following: orange flavor, mint flavor, grape flavor, cherry flavor, banana flavor, pineapple flavor, vanilla flavor, lemon flavor, aspartame, saccharin sodium, and stevioside; a lubricant (selected from one or more of the following: micropowdered silica gel, magnesium stearate, calcium stearate, stearic acid, talc, silicon dioxide, magnesium lauryl sulfate, PEG4000, and PEG6000); and a coating agent (selected from one or more of the following: acrylic resin, hydroxypropyl methylcellulose, and polyethylene glycol). The pharmaceutical excipients may also include one or more of the following: donkey-hide gelatin, salad oil, soybean lecithin, vitamin E, beeswax, safflower seed oil, low-substituted hydroxypropyl cellulose, methylcellulose, ethylcellulose, polyethylene glycol, sodium carboxymethylcellulose, microcrystalline cellulose, micropowdered silica gel, talc, and polyvinyl pyrrolidone. The active ingredient may consist of only the Chinese herbal medicine red yeast rice or functional red yeast rice or red yeast rice extract, or may consist of the Chinese herbal medicine red yeast rice or functional red yeast rice or red yeast rice extract and a second active substance. The second active substance can be one or more other Chinese medicinal materials or extracts thereof. Other Chinese medicinal materials are relative to Chinese medicinal red yeast rice or functional red yeast rice. The extracts of one or more other Chinese medicinal materials can be obtained by methods known to those skilled in the art. When extracting multiple Chinese medicinal materials (including Chinese medicinal red yeast rice or functional red yeast rice), one Chinese medicinal material can be extracted alone, and / or two or more Chinese medicinal materials can be mixed together for extraction, and / or all Chinese medicinal materials can be mixed together for extraction. In one embodiment of the present invention, the composition containing red yeast rice is a red yeast rice micro-pill, which is obtained by adding a wetting agent to the following raw materials and excipients in the following weight ratio and making pellets: 8-12 parts of red yeast rice and 3-5 parts of excipients, wherein the excipient is starch or dextrin, and the wetting agent is 60%-80% ethanol. The preparation method of the red yeast rice micro-pill comprises the following steps: a. weighing red yeast rice, drying, crushing, and passing through a 60-200 mesh sieve; b. adding starch or dextrin, using 60-80% ethanol as a wetting agent to make a soft material, and using a micro-pill machine to make pellets; the pelleting is divided into three stages, wherein the first and second stages adopt a static drying method, and the third stage adopts a high-temperature drying expansion method to form pellets; the drying temperature of the first stage is 30-40°C and the drying time is 1 hour; the drying temperature of the second stage is 50-60°C and the drying time is 1 hour; the drying temperature of the third stage is 70-80°C and the drying time is 8 hours. For the specific preparation method, reference may be made to Chinese patent application CN200510021520.1 with publication number CN1919213A. In one embodiment of the present invention, the composition containing red yeast rice is a red yeast rice soft capsule, which is a soft capsule prepared from raw materials and matrix excipients in the following weight ratio: the weight ratio of red yeast rice to matrix excipient is 1: (0.8-1.2), and the matrix excipient is soybean oil and beeswax. The preparation method of the red yeast rice soft capsule comprises the following steps: a, preparing capsule material glue: weighing raw materials containing the following weight ratio to prepare capsule material: the weight ratio of dry plasticizer to dry gelatin is (0.3-0.6): 1.0, and the weight ratio of water to dry gelatin is 1: 1; b, weighing red yeast rice, drying, crushing, and passing through a 60-200 mesh sieve; c, adding red yeast rice to soybean oil and beeswax, mixing, and preparing soft capsules by compression. The specific preparation method can refer to Chinese patent application CN200510021521.6 with publication number CN1919214A. In one embodiment of the present invention, the composition containing red yeast rice is a red yeast rice preparation, which is prepared by adding a coating agent to prepare a coated red yeast rice, and then adding excipients commonly used in pharmacy to prepare the preparation, wherein the weight ratio of the red yeast rice or its extract to the coating agent is 50-500 parts of the red yeast rice or its extract and 20-200 parts of the coating agent; the coating agent is one or more of acrylic resin, hydroxypropyl methylcellulose, and polyethylene glycol; the raw material of the red yeast rice or its extract can pass through a 60-300 mesh sieve. In particular, the red yeast rice preparation is a tablet, and its preparation method includes: a. Weighing the following weight ratios of red yeast rice or its extract and excipients: 50-500 parts of red yeast rice or its extract, and passing through a No. 4 pharmacopoeia sieve; the remaining pharmaceutical excipients include 20-200 parts of a coating agent, 0-200 parts of a filler, 10-200 parts of a disintegrant, 0-10 parts of a flavoring agent, 0-50 parts of a lubricant, and 0-10 parts of a glidant, and passing through a No. 3 pharmacopoeia sieve for later use; b. Coating the sieved red yeast rice powder or its extract with a coating agent to form an isolation coat, and passing through a No. 3 pharmacopoeia sieve for later use; c. Mixing the coated red yeast rice powder with the excipients and directly compressing the tablets to obtain the tablets. The specific preparation method can be referred to Chinese patent application CN200510022143.3 with publication number CN1969891A. In one embodiment of the present invention, the composition containing red yeast rice is a dripping pill made from red yeast rice, wherein the raw materials used to prepare the dripping pill include or consist of the following: red yeast rice extract and polyethylene glycol in a weight ratio of 1:(1-3), and the preparation method comprises: taking red yeast rice, extracting it 1-3 times with 75% ethanol, adding 2-3 times the amount of ethanol each time, extracting it for 2-3 hours each time, filtering, combining the filtrate, recovering the ethanol, and concentrating it to a concentrate with a relative density of 0.9-1.1 measured at a temperature of 55-60°C; taking another 1 / 10- 1 / 6 of the weight of red yeast rice is ground into a fine powder; a concentrated solution is continuously sprayed into the red yeast rice powder, and boiling-dried to obtain a dry extract; the dry extract is ground into a fine powder to obtain the red yeast rice extract; the boiling-drying conditions are: a material temperature of 60-80°C, and a liquid spraying rate of 25-35 liters / hour; polyethylene glycol is heated and melted, and the red yeast rice extract is added, mixed evenly, and kept warm at 75±2°C; a coolant is added dropwise using a pill making machine, wherein the coolant temperature is 20±2°C. After forming, the pills are removed, the coolant on the surface is removed, and the pills are packaged. The specific preparation method can be referred to Chinese patent application CN200510123460.4 with publication number CN1899317A. In one embodiment of the present invention, the composition containing red yeast rice is a traditional Chinese medicine red yeast rice preparation, wherein the raw material of the traditional Chinese medicine red yeast rice preparation comprises or consists of the following: 273 parts of red yeast rice and 5-10 parts of micronized silica gel. The preparation method of the traditional Chinese medicine red yeast rice preparation comprises the following steps: a. weighing the red yeast rice, drying, crushing, and sieving; b. adding excipients, granulating, and adding commonly used pharmaceutical excipients to prepare a commonly used pharmaceutical preparation. The specific preparation method can be found in Chinese patent application CN200510129372.5, published as CN1919215A. In one embodiment of the present invention, the composition containing red yeast rice is a pharmaceutical composition pill for treating cardiovascular diseases, wherein the raw materials of the pharmaceutical composition include or consist of the following: red yeast rice extract: matrix = 1: (0.5-2.0), the matrix refers to one of polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 10000, glycerol, gelatin, and poloxamer; or a mixture of polyethylene glycol 4000: polyethylene glycol 6000 = 1:1; the red yeast rice extract contains more than 33 mg / g of lovastatin as determined by HPLC. The preparation method of the red yeast rice extract comprises: taking 1 part by weight of red yeast rice, adding 1-4 parts by volume of 60-90% ethanol, refluxing and extracting for 1-4 hours, filtering the extract, adding 1-3 parts by volume of 60-90% ethanol to the residue, refluxing and extracting for 1-3 hours, filtering the extract, combining the filtrates, recovering the ethanol under reduced pressure, and concentrating the extract into a thick paste after the ethanol is completely evaporated; adding 0.5-1.25 parts by volume of deionized water to the thick paste for precipitation, allowing the mixture to stand at room temperature or under refrigeration for 2-16 hours, siphoning off the supernatant, or collecting the precipitate by centrifugation; adding 2-5% by weight of the medicinal material of fine red yeast rice powder, microcrystalline cellulose, starch, sodium carboxymethyl starch, or pregelatinized starch as an auxiliary material to the precipitate, mixing well, and drying at 60-90° C. for 6-10 hours to reduce the moisture content to less than 5%, thereby obtaining the red yeast rice extract. The specific preparation method can be referred to Chinese patent application CN200710099767.4 with publication number CN101313918A. In one embodiment of the present invention, the composition containing red yeast rice is a pharmaceutical composition having a lipid-regulating effect, wherein the raw materials of the pharmaceutical composition include or consist of the following: 1-5 parts by weight of red yeast rice and 1-5 parts by weight of kudzu root; the pharmaceutical composition is prepared by the following method: Step 1: Preparation of Red Yeast Extract I Red yeast rice extract I is prepared by any of the following methods: A, 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate each time, heat and reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a thick paste with a relative density of 0.95-1.06 measured at 55-60°C to obtain Extract I; B. To 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate each time, heat under reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a relative density of 0.95-1.06 measured at 55-60°C. Add 0.5-2.0 times the amount of deionized water to the concentrate and mix well. Place at room temperature or refrigerate for 2-12 hours, centrifuge, collect the precipitate, and dry to obtain Extract I; Step 2: Preparation of Pueraria Extract II 1 part by weight of Pueraria root is added with 4-20 parts by volume of water or ethanol each time, heated under reflux for 1-3 hours, extracted 2-4 times, filtered, the filtrate is combined, the solvent is recovered, and concentrated into a thick paste to obtain Extract II; Step 3: Preparation Extract I and Extract II are prepared into clinically acceptable pills, powders, tablets, granules, capsules or oral liquid preparations by conventional methods and adding conventional excipients. For the specific preparation method, reference can be made to Chinese patent application CN201210118280.7 with publication number CN103372051A. In one embodiment of the present invention, the composition containing red yeast rice is a pharmaceutical composition having the effect of regulating blood lipids, wherein the raw materials of the pharmaceutical composition include or consist of the following: 1-5 parts by weight of red yeast rice, 1-5 parts by weight of oriental rhizome; The pharmaceutical composition is prepared by the following method: Step 1: Preparation of Red Yeast Extract I Red yeast rice extract I is prepared by any of the following methods: A, 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate each time, heat and reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a thick paste with a relative density of 0.95-1.06 measured at 55-60°C to obtain Extract I; B. To 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate each time, heat under reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a relative density of 0.95-1.06 measured at 55-60°C. Add 0.5-2.0 times the amount of deionized water to the concentrate and mix well. Place at room temperature or refrigerate for 2-12 hours, centrifuge, collect the precipitate, and dry to obtain Extract I; Step 2: Preparation of Alisma Orientalis Extract II 1 part by weight of Alisma orientalis is added with 4-20 parts by volume of water or ethanol each time, heated under reflux for 1-3 hours, extracted 2-4 times, filtered, the filtrate is combined, the solvent is recovered, and concentrated into a thick paste to obtain Extract II; Step 3: Preparation Extract I and Extract II are prepared into clinically acceptable pills, powders, tablets, granules, capsules or oral liquid preparations by conventional methods and adding conventional excipients. For the specific preparation method, reference may be made to Chinese patent application CN201210118859.3 with publication number CN103372114A. In one embodiment of the present invention, the composition containing red yeast rice is a pharmaceutical composition having the effect of regulating blood lipids, and the raw materials of the pharmaceutical composition include or consist of the following: 1-5 parts by weight of red yeast rice and 1-5 parts by weight of hawthorn. The pharmaceutical composition is prepared by the following method: Step 1: Preparation of Red Yeast Extract I Red yeast rice extract I was prepared by any of the following methods: To 1 part by weight of red yeast rice (A), add 2-10 parts by volume of 50-90% ethanol, methanol, or ethyl acetate each time, heat under reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a thick paste with a relative density of 0.95-1.06 measured at 55-60°C to obtain Extract I; B. To 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol, or ethyl acetate, heat under reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a relative density of 0.95-1.06 measured at 55-60°C. Add 0.5-2.0 times the amount of deionized water to the concentrate, mix well, store at room temperature or refrigerate for 2-12 hours, centrifuge, collect the precipitate, and dry to obtain Extract I; Step 2: Preparation of Hawthorn Extract II 1 part by weight of hawthorn medicinal material is added with 4-20 parts by volume of water or ethanol each time, heated under reflux for 1-3 hours, extracted 2-4 times, filtered, the filtrate is combined, the solvent is recovered, and concentrated into a thick paste to obtain Extract II; Step 3: Preparation Extract I and Extract II are prepared into clinically acceptable pills, powders, tablets, granules, capsules or oral liquid preparations by conventional methods and adding conventional excipients. For the specific preparation method, please refer to Chinese patent application CN201210119095.X with publication number CN103372073A. In one embodiment of the present invention, the composition containing red yeast rice is a pharmaceutical composition having the effect of regulating blood lipids, wherein the raw materials of the pharmaceutical composition include or consist of the following: 1-5 parts by weight of red yeast rice, 1-5 parts by weight of Chuanxiong; The pharmaceutical composition is prepared by the following method: Step 1: Preparation of Red Yeast Extract I Red yeast rice extract I is prepared by any of the following methods: A, 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate each time, heat and reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a thick paste with a relative density of 0.95-1.06 measured at 55-60°C to obtain Extract I; B. To 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate each time, heat under reflux for 1-3 hours, and extract 2-3 times; filter the extract, combine the filtrates, recover the solvent, and concentrate to a relative density of 0.95-1.06 measured at 55-60°C. Add 0.5-2.0 times the amount of deionized water to the concentrate and mix well. Place at room temperature or refrigerate for 2-12 hours, centrifuge, collect the precipitate, and dry to obtain Extract I; Step 2: Preparation of Chuanxiong Extract II 1 part by weight of Chuanxiong is added with 4-20 parts by volume of water or ethanol each time, and the mixture is heated under reflux for 1-3 hours, and extracted 2-4 times. The extract is filtered, the filtrate is combined, the solvent is recovered, and the mixture is concentrated into a thick paste to obtain Extract II. Step 3: Preparation Extract I and Extract II are prepared into clinically acceptable pills, powders, tablets, granules, capsules or oral liquid preparations by conventional methods and adding conventional excipients. For the specific preparation method, reference may be made to Chinese patent application CN201210119116.8 with publication number CN103372040A. In one embodiment of the present invention, the composition containing red yeast rice is a pharmaceutical composition for regulating blood lipids, comprising a red yeast rice extract and a gynostemma pentaphyllum extract; the weight ratio of the red yeast rice to the gynostemma pentaphyllum medicinal materials is 1:10 to 10:1; the weight percentage of total saponins in the gynostemma pentaphyllum extract is ≥8%; Wherein, the Gynostemma pentaphyllum extract is prepared by the following method: Take 1 part by weight of Gynostemma pentaphyllum, add 4-20 parts by volume of water or ethanol or ethanol solution each time, heat and extract for 1-3 hours, extract 2-4 times, filter the extract, combine the filtrate, recover the solvent, and concentrate into a thick paste; The red yeast rice extract is prepared by method I or method II: Method I: 1) Take 1 part by weight of red yeast rice, add 2-10 parts by volume of 50-90% ethanol, methanol or ethyl acetate, heat under reflux for 1-3 hours, and extract 2-3 times; 2) filtering the extract and combining the filtrates; 3) concentrating the filtrate obtained in step 2) into a thick paste; Method II: (1) Take 1 part by weight of red yeast rice, add 3 parts by volume of 75% ethanol each time, heat and reflux for 2-3 hours, and extract twice; (2) filtering the extract and combining the filtrates; (3) Concentrating the filtrate obtained in step (2) to a concentrated solution having a relative density of 0.95-1.06 at 55-60°C. For the specific preparation method, reference may be made to Chinese patent application CN201210155323.9 with publication number CN103417601A. In one embodiment of the present invention, the composition containing red yeast rice is a medicament, wherein the raw material composition for preparing the active ingredient of the medicament includes or consists of the following: 6 parts of red yeast rice, 9 parts of white atractylodes, and 12 parts of hawthorn; or 3-6 parts red yeast rice, 9-12 parts white atractylodes, 12 parts hawthorn; or 3-15 parts of red yeast rice, 3-15 parts of white atractylodes, and 3-15 parts of hawthorn; or 6 parts of red yeast rice, 9 parts of rhizome of Alisma orientalis, 9 parts of atractylodes macrocephala, and 12 parts of hawthorn; or 3-6 parts of red yeast rice, 6-9 parts of rhizome of Alisma orientalis, 9-12 parts of atractylodes macrocephala, and 12 parts of hawthorn; 3-15 parts of red yeast rice, 3-15 parts of rhizome of Alisma orientalis, 3-15 parts of atractylodes macrocephala, and 3-15 parts of hawthorn; The preparation method of the drug comprises the following steps: a. Weighing Chinese medicinal materials as raw materials; b. Extracting the above medicinal materials with alcohol or aqueous ethanol, filtering to obtain filtrate A; c. Recovering ethanol from filtrate A and concentrating under reduced pressure to obtain extract B; d. Adding an appropriate amount of water to extract B, allowing it to stand, and centrifuging to obtain supernatant C and precipitate D, drying precipitate D to obtain active ingredient I; e. Passing supernatant C through a pretreated resin column, washing with water until colorless, then washing with ethanol until colorless, collecting the eluate, recovering ethanol, concentrating and drying to obtain a thick paste E as active ingredient II; f. Mixing active ingredients I and II with pharmaceutically acceptable excipients to prepare a pharmaceutical preparation. For the specific preparation method, reference can be made to Chinese patent application CN200310110995.9, publication number CN1618441A. For example, the composition containing red yeast rice can be a Chinese patent medicine made from red yeast rice, which can be commercially obtained under the trade names of Zhibitai, Zhibituo, Xuezhikang, etc. The above-mentioned Chinese medicine red yeast rice, functional red yeast rice, red yeast rice extract and composition containing red yeast rice all contain a certain amount of active ingredient monacolin compounds, and the monacolin compounds include monacolin K, and optionally, monacolin L and dehydrated lovastatin, and further optionally, contain one or more compounds selected from the following: monacolin L, dehydrated lovastatin, monacolin M, monacolin N1, monacolin N2, ... monacolin L, dehydrated lovastatin, monacolin M, monacolin N1, monacolin N2, monacolin K, and monacolin L, dehydrated lovastatin, monacolin Monacolin N3, monacolin N4, monacolin N5, monacolin N6, monacolin Q, monacolin R, monacolin S, monacolin T, monacolin U, monacolin X, monacolin acid A, dehydromonacolin J, dehydromonacolin K, dehydromonacolin L, dehydromonacolin N, dihydromonacolin K, dihydromonacolin L, dihydromonacolin MV, dehydromonacolin MV2 and monacolin K ethyl ester. In this article, unless otherwise specified, the effective amount, therapeutically effective amount and content of red yeast rice are all calculated based on the active ingredient monacolin K. Monacolin compounds have two structures: open ring and closed ring. In the present invention, the content of each monacolin compound refers to the sum of the open ring structure and the closed ring structure. The method for determining the content of monacolin K in red yeast rice is known in the prior art, for example, refer to: Light Industry Standard of the People's Republic of China QB / T 2847-2023 Functional Red Yeast Rice (Powder); Hao Shengyuan et al. Determination of lovastatin and lovastatin acid in red yeast rice and Zhibituo tablets by one test and multiple evaluation method [J]. Chinese Journal of Experimental Traditional Chinese Medicine, 2017, 23(5): 74-78; Li Xuemei et al. Determination of the content of lovastatin and lovastatin acid in Xuezhikang capsules by HPLC [J]. Chinese Pharmacist, 2012, 15(2): 164-166; Li Yan et al. Simultaneous determination of fat by HPLC Contents of three monacolin components in Bituo tablets, Journal of Pharmaceutical Analysis, 2011, 31(2), pp. 270-273; Wang Lijuan et al., Determination of the content of monacolin components in Xuezhikang capsules by HPLC, Chinese Journal of Convalescent Medicine, 2015, 24(5), pp. 479-481; Wen Zhongming et al., Determination of the content of red yeast rice in Zhibitai capsules, Drug Identification, 2011, 20(13), pp. 21-23. When it is clearly stated that the content of monacolin compounds is measured, the content of monacolin compounds refers to the total amount of monacolin K, monacolin L and / or dehydrated lovastatin, for example, the total amount of monacolin K and monacolin L and / or dehydrated lovastatin, more particularly the total amount of monacolin K, monacolin L and dehydrated lovastatin, which can be determined, for example, by referring to the methods reported in the literature (Li Yan et al., Simultaneous determination of the content of three monacolin components in Zhibituo tablets by HPLC, Journal of Pharmaceutical Analysis, 2011, 31(2), pp. 270-273; Wang Lijuan et al., Determination of the content of monacolin components in Xuezhikang capsules by HPLC, Chinese Journal of Convalescent Medicine, 2015, 24(5), pp. 479-481). It should also be understood that the various embodiments of red yeast rice measured in terms of monacolin K in the following text can also be replaced by measuring in terms of monacolin compounds without affecting the technical effects of the present invention. Monacolin K synthesized by microbial fermentation is all open-ring structure, but during the subsequent drying and storage process, the open-ring structure of monacolin K will partially convert to a closed-ring structure. The efficacy of the open-ring structure of monacolin K is twice that of the closed-ring structure. As early as 2003, Zhu Hua et al. (Zhu Hua, Xu Ganrong, Chen Yun. Determination of acid-type and lactone-type monacolin K in red yeast rice by HPLC [J]. Journal of Wuxi University of Light Industry, 2003, 22(3):46-52.) published a paper using high-performance liquid chromatography (HPLC) to simultaneously detect open-ring and closed-ring monacolin K. The monacolin K detection method in the "Functional Red Yeast Rice (Powder)" standard issued by the light industry also detects both structures simultaneously. In a first aspect, the present invention provides a pharmaceutical combination comprising probucol and a statin. The statin is selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. In some embodiments, the drug combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of a statin. In some embodiments, the therapeutically effective amount of probucol is from about 10 mg to about 1000 mg (preferably, excluding the endpoint value of 1000 mg). In some embodiments, the therapeutically effective amount of probucol is from about 20 mg to about 800 mg. In some embodiments, the therapeutically effective amount of probucol is from about 20 mg to about 400 mg. In some embodiments, the therapeutically effective amount of probucol is from about 40 mg to about 400 mg. In some embodiments, the therapeutically effective amount of probucol is from about 60 mg to about 250 mg. In some embodiments, the therapeutically effective amount of probucol is about 20 mg, 25 mg, 30 mg, 31.25 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 62.5 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 187.5 mg, 190 mg, 195 mg, 200 mg. In a preferred embodiment, the therapeutically effective amount of probucol is from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg. The "therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more times (such as twice or three times) per day. In some embodiments, the drug combination comprises a therapeutically effective amount of a statin. In some embodiments, the therapeutically effective amount of a statin is about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg. In some embodiments, the therapeutically effective amount of a statin is about 2 mg to about 80 mg. In some embodiments, the therapeutically effective amount of a statin is about 5 to about 80 mg. In some embodiments, the therapeutically effective amount of a statin is about 10 to about 80 mg. In some embodiments, the therapeutically effective amount of a statin is about 20 to about 80 mg. In some embodiments, the therapeutically effective amount of a statin is about 5 to about 40 mg. In some embodiments, the therapeutically effective amount of a statin is about 20 to about 40 mg. In some embodiments, the therapeutically effective amount of a statin is about 10 to about 20 mg. In some embodiments, the therapeutically effective amount of a statin is about 1 to about 5 mg. In a preferred embodiment, the therapeutically effective amount of a statin is about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg, or about 2 mg to about 80 mg. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (e.g., twice or three times) per day. In some embodiments, the statin is lovastatin, and its therapeutically effective amount is about 5 mg to about 40 mg, about 10 mg to about 40 mg, or about 10 mg to about 20 mg. In some embodiments, the therapeutically effective amount of lovastatin is about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg. In a preferred embodiment, the therapeutically effective amount of lovastatin is about 5 mg to about 40 mg or about 10 mg to about 20 mg. "Therapeutically effective amount" in this paragraph refers to the dosage administered to the subject (or patient) on a single day, and can be administered once or multiple times (such as 2 or 3 times) per day. In some embodiments, the statin is pravastatin, and its therapeutically effective amount is about 5 mg to about 40 mg, about 10 mg to about 40 mg, or about 10 mg to about 20 mg. In some embodiments, the therapeutically effective amount of pravastatin is about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg. In a preferred embodiment, the therapeutically effective amount of pravastatin is about 7.5 mg to about 40 mg, for example, 30 mg, or about 15 mg. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (such as twice or three times) per day. In some embodiments, the statin is simvastatin, and its therapeutically effective amount is about 5 mg to about 80 mg, about 10 mg to about 80 mg, about 5 mg to about 40 mg, about 10 mg to about 40 mg, or about 20 mg to about 40 mg. In some embodiments, the therapeutically effective amount of simvastatin is about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg. In a preferred embodiment, the therapeutically effective amount of simvastatin is about 10 mg to about 40 mg, or about 20 mg to about 40 mg. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (such as 2 or 3 times) per day. In some embodiments, the statin is fluvastatin, and its therapeutically effective amount is about 5 mg to about 80 mg, about 10 mg to about 80 mg, about 20 mg to about 80 mg, about 10 mg to about 60 mg, or about 20 mg to about 40 mg. In some embodiments, the therapeutically effective amount of fluvastatin is about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, or about 80 mg. In preferred embodiments, the therapeutically effective amount of fluvastatin is about 20 mg to about 80 mg, or about 40 mg to about 80 mg. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (e.g., twice or three times) per day. In some embodiments, the statin is atorvastatin, and its therapeutically effective amount is about 5 mg to about 80 mg, about 10 mg to about 80 mg, about 5 mg to about 40 mg, about 10 mg to about 40 mg, or about 10 mg to about 20 mg. In some embodiments, the therapeutically effective amount of atorvastatin is about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, or about 80 mg. In a preferred embodiment, the therapeutically effective amount of atorvastatin is about 5 mg to about 40 mg, or about 10 mg to about 20 mg. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (such as twice or three times) per day. In some embodiments, the statin is rosuvastatin, and its therapeutically effective amount is about 2.5 mg to about 40 mg, about 2.5 mg to about 20 mg, about 5 mg to about 20 mg, or about 10 mg to about 20 mg. In some embodiments, the therapeutically effective amount of rosuvastatin is about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg. In a preferred embodiment, the therapeutically effective amount of rosuvastatin is about 5 mg to about 20 mg, or about 5 mg to about 10 mg. "Therapeutically effective amount" in this paragraph refers to the dosage administered to the subject (or patient) on a single day, and can be administered once or more (such as 2 or 3 times) per day. In some embodiments, the statin is pitavastatin, and its therapeutically effective amount is about 0.5 mg to about 4 mg, about 1 mg to about 4 mg, about 2 mg to about 4 mg, about 2.5 mg to about 4 mg, about 3 mg to about 4 mg, or about 3.5 mg to about 4 mg. In some embodiments, the therapeutically effective amount of pitavastatin is about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, or about 4 mg. In a preferred embodiment, the therapeutically effective amount of pitavastatin is about 1 mg to about 4 mg, or about 2 mg to about 4 mg. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (such as 2 or 3 times) per day. Any weight of the therapeutically effective amount of probucol within the above range and any weight of the therapeutically effective amount of any statin within the above range may constitute the pharmaceutical composition mentioned in the present invention. In the present invention, the drug combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of a statin, wherein the therapeutically effective amount of probucol and the therapeutically effective amount of the statin are such amounts: the amount of probucol is 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein a and b are integers of 1-16, and a≤b; the amount of statins is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein c and d are integers of 1-16, and c≤d, for example, c≤d / 2. With the development of medicine and changes in human physique, if new conventional daily doses of probucol for lowering cholesterol and conventional daily doses of statins for lowering cholesterol are updated or proposed in the future "Guidelines for Chinese Blood Lipid Management" or other authoritative guidelines, the amount of probucol shall be 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein a and b are integers of 1-16 and a≤b, and the amount of statins shall be c / d of the maximum daily dose of statins for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein c and d are integers of 1-16 and c≤d, for example, c≤d / 2. The amount of probucol is a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the Guidelines for Blood Lipid Management in China (2023), wherein a and b are integers from 1 to 16, and a ≤ b, and the amount of statin is c / d of the maximum daily dose of statin for lowering cholesterol recommended in the Guidelines for Blood Lipid Management in China (2023), wherein c and d are integers from 1 to 16, and c ≤ d, for example, c ≤ d / 2; or The amount of probucol is 3a / 4b or 5a / 16b of the maximum daily dose of probucol for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein a and b are integers of 1-16, and a≤b, and the amount of statins is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein c and d are integers of 1-16, and c≤d, for example, c≤d / 2. The maximum daily doses of probucol for cholesterol-lowering and statins for cholesterol-lowering recommended in the "Guidelines for Chinese Blood Lipid Management (2023)" are (see Section 9.1.4 and Table 12 of the "Guidelines for Chinese Blood Lipid Management (2023)"): probucol: 1000 mg, lovastatin: 40 mg, pravastatin: 40 mg, simvastatin: 40 mg, fluvastatin: 80 mg, atorvastatin: 80 mg, rosuvastatin: 20 mg, and pitavastatin: 4 mg. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of lovastatin, wherein the weight ratio of probucol to lovastatin is about (0.25-80):1. In some embodiments, the weight ratio of probucol to lovastatin is about (0.5-80):1. In some embodiments, the weight ratio of probucol to lovastatin is about (0.5-50):1. In some embodiments, the weight ratio of probucol to lovastatin is about (1-40):1. In some embodiments, the weight ratio of probucol to lovastatin is about (1-25):1. In some embodiments, the weight ratio of probucol to lovastatin is about (3-40):1. In some embodiments, the weight ratio of probucol to lovastatin is about 0.25:1, 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, or 40:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of lovastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 5 to about 40 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 10 to about 40 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 10 to about 40 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 10 to about 40 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 5 mg to about 40 mg, or about 10 mg to about 20 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 5 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 10 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 20 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 5 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 10 mg of lovastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 20 mg of lovastatin. "Therapeutically effective amount" in this paragraph refers to the dose administered to the subject (or patient) in a single day, and can be administered once or more (such as 2 or 3 times) per day. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of pravastatin, wherein the weight ratio of probucol to pravastatin is about (0.25-80):1. In some embodiments, the weight ratio of probucol to pravastatin is about (0.5-80):1. In some embodiments, the weight ratio of probucol to pravastatin is about (0.5-50):1. In some embodiments, the weight ratio of probucol to pravastatin is about (1-40):1. In some embodiments, the weight ratio of probucol to pravastatin is about (1-25):1. In some embodiments, the weight ratio of probucol to pravastatin is about (6-10):1. In some embodiments, the weight ratio of probucol to pravastatin is about 0.25:1, 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 25:3, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of pravastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 5 to about 40 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 10 to about 40 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 10 to about 40 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 10 to about 40 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 5 mg to about 40 mg, or about 7.5 mg to about 30 mg, or about 15 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 10 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 15 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 20 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 10 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 15 mg of pravastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 20 mg of pravastatin. "Therapeutically effective amount" in this paragraph refers to the dose administered to the subject (or patient) in a single day, and can be administered once or more (such as twice or three times) per day. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of simvastatin, wherein the weight ratio of probucol to simvastatin is about (0.25-160):1. In some embodiments, the weight ratio of probucol to simvastatin is about (0.5-160):1. In some embodiments, the weight ratio of probucol to simvastatin is about (0.5-80):1. In some embodiments, the weight ratio of probucol to simvastatin is about (1-40):1. In some embodiments, the weight ratio of probucol to simvastatin is about (1-25):1. In some embodiments, the weight ratio of probucol to simvastatin is about (1-15):1. In some embodiments, the weight ratio of probucol to simvastatin is about 0.25:1, 0.5:1, 1:1, 25:16, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of simvastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 2.5 to about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 5 to about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 5 to about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 10 to about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 5 mg to about 80 mg, or about 5 mg to about 40 mg, or about 10 mg to about 40 mg, or about 20 mg to about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 10 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 20 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 10 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 20 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 40 mg of simvastatin. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of fluvastatin, wherein the weight ratio of probucol to fluvastatin is about (0.125-40):1. In some embodiments, the weight ratio of probucol to fluvastatin is about (0.125-20):1. In some embodiments, the weight ratio of probucol to fluvastatin is about (0.25-20):1. In some embodiments, the weight ratio of probucol to fluvastatin is about (0.5-20):1. In some embodiments, the weight ratio of probucol to fluvastatin is about (0.5-10):1. In some embodiments, the weight ratio of probucol to fluvastatin is about (0.5-8):1. In some embodiments, the weight ratio of probucol to fluvastatin is about (1-4):1. In some embodiments, the weight ratio of probucol to fluvastatin is about 0.25:1, 0.5:1, 1:1, 25:16, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of fluvastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 10 to about 80 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 20 to about 80 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 20 to about 80 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 30 to about 80 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 10 mg to about 80 mg, or about 20 mg to about 80 mg, or about 40 mg to about 80 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 40 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 60 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 80 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 40 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 60 mg of fluvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 80 mg of fluvastatin. "Therapeutically effective amount" in this paragraph refers to the dose administered to the subject (or patient) in a single day, and can be administered once or more (such as twice or three times) per day. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of atorvastatin, wherein the weight ratio of probucol to atorvastatin is about (0.5-80):1. In some embodiments, the weight ratio of probucol to atorvastatin is about (0.5-50):1. In some embodiments, the weight ratio of probucol to atorvastatin is about (1-40):1. In some embodiments, the weight ratio of probucol to atorvastatin is about (3-25):1. In some embodiments, the weight ratio of probucol to atorvastatin is about (2-25):1. In some embodiments, the weight ratio of probucol to atorvastatin is about 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of atorvastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 5 to about 80 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 10 to about 80 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 10 to about 80 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 10 to about 40 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 5 mg to about 40 mg, or about 5 mg to about 20 mg, or about 10 mg to about 20 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 20 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 10 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 15 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 20 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 10 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 15 mg of atorvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 20 mg of atorvastatin. The "therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more times (such as twice or three times) per day. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of rosuvastatin, wherein the weight ratio of probucol to rosuvastatin is about (1-160):1. In some embodiments, the weight ratio of probucol to rosuvastatin is about (1-80):1. In some embodiments, the weight ratio of probucol to rosuvastatin is about (1-60):1. In some embodiments, the weight ratio of probucol to rosuvastatin is about (1-50):1. In some embodiments, the weight ratio of probucol to rosuvastatin is about (5-60):1. In some embodiments, the weight ratio of probucol to rosuvastatin is about 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1 , 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, 25:1, 26:1, 28:1, 30:1, 32:1, 34:1, 36:1, 38:1, 40:1, 42:1, 44:1, 46:1, 48:1, 50:1, 52:1, 54:1, 56:1, 58:1, or 60:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of rosuvastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 2.5 to about 20 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 5 to about 20 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 5 to about 20 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 5 to about 20 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 2.5 mg to about 20 mg, or about 5 mg to about 10 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 10 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 5 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 10 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 15 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 5 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 10 mg of rosuvastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 15 mg of rosuvastatin. The "therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more times (such as twice or three times) per day. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of pitavastatin, wherein the weight ratio of probucol to pitavastatin is about (10-400):1. In some embodiments, the weight ratio of probucol to pitavastatin is about (15-250):1. In some embodiments, the weight ratio of probucol to pitavastatin is about (20-200):1. In some embodiments, the weight ratio of probucol to pitavastatin is about (30-125):1. In some embodiments, the weight ratio of probucol to pitavastatin is about (80-150):1. In some embodiments, the weight ratio of probucol to pitavastatin is about 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 125:1, 150:1, 200:1, or 250:1. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of pitavastatin, wherein the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 1 to about 4 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 2 to about 4 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 2 to about 4 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 60 to about 250 mg of probucol and about 1 to about 3 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg of probucol and about 0.5 mg to about 4 mg, about 1 mg to about 4 mg, or about 2 mg to about 4 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 2 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 3 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 4 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 2 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 3 mg of pitavastatin. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 4 mg of pitavastatin. "Therapeutically effective amount" in this paragraph refers to the dose administered to a subject (or patient) in a single day, and can be administered once or more (such as 2 or 3 times) per day. In some embodiments, probucol or a pharmaceutically acceptable salt thereof and the statin are provided in separate formulations. In some embodiments, probucol is provided in the form of a probucol tablet. In some embodiments, the statin is provided in the form of a tablet, capsule, or granule. In some embodiments, probucol and statins are provided in a single composition, for example, in a single tablet, capsule, or granule. In some embodiments, probucol and statins can also be provided in a plurality (e.g., 2, 3, 4, 5, 6, 7, 8, 9) of compositions, for example, in a plurality (e.g., 2, 3, 4, 5, 6, 7, 8, 9) of tablets, capsules, or granules, wherein the therapeutically effective amount of probucol and the therapeutically effective amount of statins are evenly distributed in the plurality (e.g., 2, 3, 4, 5, 6, 7, 8, 9) of compositions (e.g., tablets, capsules, or granules). The form of the composition is not limited to the tablets, capsules, or granules described above. In a second aspect, the present invention provides a pharmaceutical composition comprising probucol, a statin and a pharmaceutically acceptable carrier. In the present invention, the amount of probucol and the amount of statin in the pharmaceutical composition are such that the amount of probucol is 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein a and b are integers of 1-16, and a≤b; the amount of statin is c / d of the maximum daily dose of statin for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein c and d are integers of 1-16, and c≤d, for example, c≤d / 2. With the development of medicine and changes in human physique, if new conventional daily doses of probucol for lowering cholesterol and conventional daily doses of statins for lowering cholesterol are updated or proposed in the future "Guidelines for Chinese Blood Lipid Management" or other authoritative guidelines, the amount of probucol shall be 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein a and b are integers of 1-16 and a≤b, and the amount of statins shall be c / d of the maximum daily dose of statins for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein c and d are integers of 1-16 and c≤d, for example, c≤d / 2. In some embodiments, the pharmaceutical composition comprises about 0.1% to 99.5% by weight of the active ingredient (i.e., probucol and statins), preferably about 0.5% to 99.5% by weight, more preferably about 1% to 50% by weight, for example, about 1%, about 1.5%, about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or about 50% by weight of the active ingredient. The remainder of the pharmaceutical composition is a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises two, three or more pharmaceutically acceptable carriers. Examples of the pharmaceutically acceptable carrier include, but are not limited to, conventional diluents in the pharmaceutical field (such as, but not limited to, water, ethanol, propylene glycol, glycerol, lactose, dextrose, sucrose, cellulose, corn starch, potato starch), excipients (such as, but not limited to, sodium citrate, calcium carbonate, calcium phosphate), fillers (such as, but not limited to, lactose, high molecular weight polyethylene glycol), binders (such as, but not limited to, polyvinyl pyrrolidone, sucrose, gelatin, gum arabic, starch, methylcellulose, carboxymethylcellulose), wetting agents (such as, but not limited to, lecithin, polysorbate, lauryl sulfate), disintegrants (such as, but not limited to, starch, alginic acid, alginates, sodium starch glycolate), lubricants (such as, but not limited to, sodium lauryl sulfate, talc, silicon dioxide, stearic acid, magnesium stearate, calcium stearate, polyethylene glycol), colorants, flavors, absorption enhancers, surfactants, adsorption carriers, etc. In some embodiments, the pharmaceutical composition comprises probucol and lovastatin as active ingredients, wherein the weight ratio of probucol to lovastatin is about (0.5-80): 1, about (0.5-50): 1, about (1-40): 1, about (3-40): 1, or about (1-25): 1. In some embodiments, the weight ratio of probucol to lovastatin is about 0.25: 1, 0.5: 1, 1: 1, 2: 1, 3: 1, 3.125: 1, 4: 1, 5: 1, 6: 1, 6.25: 1, 7: 1, 8: 1, 9: 1, 9.375: 1, 10: 1, 11: 1, 12: 1, 12.5: 1, 13: 1, 14: 1, 15: 1, 15.625: 1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, or 40:1. In some embodiments, the pharmaceutical composition comprises probucol and pravastatin as active ingredients, wherein the weight ratio of probucol to pravastatin is about (0.5-80):1, about (0.5-50):1, about (1-40):1, about (6-10):1 or about (1-25):1. In some embodiments, the weight ratio of probucol to pravastatin is about 0.25:1, 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 25:3, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical composition comprises probucol and simvastatin as active ingredients, wherein the weight ratio of probucol to simvastatin is about (0.5-160):1, about (0.5-80):1, about (1-40):1, about (1-25):1 or about (1-15):1. In some embodiments, the weight ratio of probucol to simvastatin is about 0.25:1, 0.5:1, 1:1, 25:16, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical composition comprises probucol and fluvastatin as active ingredients, wherein the weight ratio of probucol to fluvastatin is (0.125-40):1, about (0.125-20):1, about (0.25-20):1, about (0.5-20):1, about (0.5-10):1, about (1-4):1 or about (0.5-8):1. In some embodiments, the weight ratio of probucol to fluvastatin is about 0.25:1, 0.5:1, 1:1, 25:16, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical composition comprises probucol and atorvastatin as active ingredients, wherein the weight ratio of probucol to atorvastatin is about (0.5-80):1, about (0.5-50):1, about (1-40):1, about (3-25):1 or about (2-25):1. In some embodiments, the weight ratio of probucol to atorvastatin is about 0.25:1, 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some embodiments, the pharmaceutical composition comprises probucol and rosuvastatin as active ingredients, wherein the weight ratio of probucol to rosuvastatin is about (1-160): 1, about (1-80): 1, about (1-60): 1, about (1-50): 1, or about (5-60): 1. In some embodiments, the weight ratio of probucol to rosuvastatin is about 0.25: 1, 0.5: 1, 1: 1, 2: 1, 3: 1, 3.125: 1, 4: 1, 5: 1, 6: 1, 6.25: 1, 7: 1, 8: 1, 9: 1, 9.375: 1, 10: 1, 11: 1, 12: 1, 12.5: 1, 13: 1, 14: 1, 15: 1, 15.625: 1, 16: 1, 17: :1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1 or 25:1, 26:1, 28:1, 30:1, 32:1, 34:1, 36:1, 38:1, 40:1, 42:1, 44:1, 46:1, 48:1, 50:1, 52:1, 54:1, 56:1, 58:1, or 60:1. In some embodiments, the pharmaceutical composition comprises probucol and pitavastatin as active ingredients, wherein the weight ratio of probucol to pitavastatin is about (10-400): 1, about (15-250): 1, about (20-200): 1, about (30-125): 1, or about (80-150): 1. In some embodiments, the weight ratio of probucol to pitavastatin is about 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1, 100: 1, 125: 1, 150: 1, 200: 1, or 250: 1. In some embodiments, the pharmaceutical composition is prepared into a pharmaceutically acceptable dosage form. For example, in some embodiments, probucol and statins can be mixed with one or more pharmaceutically acceptable carriers and prepared into a pharmaceutically acceptable dosage form according to conventional production methods in the pharmaceutical field. Examples of the pharmaceutically acceptable dosage form include, but are not limited to, conventional solid dosage forms in the pharmaceutical field (such as, but not limited to, tablets (including ordinary tablets, coated tablets, chewable tablets, enteric-coated tablets, sustained-release tablets, controlled-release tablets, orally disintegrating tablets, dispersible tablets, effervescent tablets, etc.), capsules (including hard capsules, soft capsules, enteric-coated capsules, sustained-release capsules, controlled-release capsules, etc.), granules (including soluble granules, suspension granules, enteric-coated granules, sustained-release granules, controlled-release granules, effervescent granules, etc.), pills, micropills, etc.), liquid dosage forms (such as, but not limited to, solutions, syrups, suspensions, emulsions, etc.), etc. In some embodiments, the pharmaceutical composition is in a unit dosage form suitable for oral administration, such as a tablet, capsule, or granule, each containing a predetermined amount of active ingredient. In some embodiments, the pharmaceutical composition is a capsule. In some embodiments, the pharmaceutical composition is a tablet. In some embodiments, the pharmaceutical composition is a chewable tablet. In some embodiments, the pharmaceutical composition is a multi-layer tablet, such as a bi-layer tablet, wherein the first layer contains probucol and a pharmaceutically acceptable carrier, and the second layer contains a statin and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is an oral unit dosage form containing a therapeutically effective amount of probucol, a statin, and a pharmaceutically acceptable carrier. In some embodiments, the amount of probucol in the oral unit dosage form can vary in the range of about 10 mg to about 1000 mg, for example, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 40 mg to about 400 mg, about 60 mg to about 250 mg, about 31.25 mg, about 62.5 mg, about 125 mg, about 187.5 mg, about 250 mg, about 312.5 mg, or about 375 mg. In some embodiments, the amount of statin in the oral unit dosage form can vary in the range of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg, for example, about 5 mg to about 80 mg, about 5 mg to about 40 mg, about 5 mg to about 20 mg, or about 1 mg to about 5 mg. In a preferred embodiment, in the oral unit dosage form, the content of probucol can be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of the statin can be about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg, or about 2 mg to about 80 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 5 mg to about 40 mg of lovastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 5 mg to about 40 mg of lovastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 10 mg to about 20 mg of lovastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg of probucol and about 20 mg of lovastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 20 mg of lovastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 10 mg of lovastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 20 mg of lovastatin. In preferred embodiments, in the oral unit dosage form, the content of probucol may be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of lovastatin may be about 5 mg to about 40 mg, or about 10 mg to about 20 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 5 mg to about 40 mg of pravastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 5 mg to about 40 mg of pravastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 10 mg to about 40 mg of pravastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 15 mg of probucol and about 125 mg of probucol and about 15 mg of pravastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 15 mg of pravastatin. In preferred embodiments, in the oral unit dosage form, the content of probucol may be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of pravastatin may be about 5 mg to about 40 mg, or about 7.5 mg to about 30 mg, or about 15 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 2.5 mg to about 40 mg of simvastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 2.5 mg to about 40 mg of simvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 10 mg to about 40 mg of simvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 40 mg of probucol and about 40 mg of simvastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 40 mg of simvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 40 mg of simvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 20 mg of simvastatin. In a preferred embodiment, in the oral unit dosage form, the content of probucol can be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of simvastatin can be about 5 mg to about 80 mg, or about 5 mg to about 40 mg, or about 10 mg to about 80 mg, or about 20 mg to about 40 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 10 mg to about 80 mg of fluvastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 10 mg to about 80 mg of fluvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 20 mg to about 40 mg of fluvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg of probucol and about 40 mg of fluvastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 40 mg of fluvastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 80 mg of fluvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 40 mg of fluvastatin. In preferred embodiments, in the oral unit dosage form, the content of probucol may be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of fluvastatin may be about 10 mg to about 80 mg, or about 20 mg to about 80 mg, or about 40 mg to about 80 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 5 mg to about 80 mg of atorvastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 5 mg to about 80 mg of atorvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 10 mg to about 40 mg of atorvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg of probucol and about 20 mg of atorvastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 20 mg of atorvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 20 mg of atorvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 10 mg of atorvastatin. In preferred embodiments, the content of probucol in the oral unit dosage form can be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of atorvastatin can be about 5 mg to about 40 mg, or about 5 mg to about 20 mg, or about 10 mg to about 20 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 2.5 mg to about 20 mg of rosuvastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 2.5 mg to about 20 mg of rosuvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 5 mg to about 20 mg of rosuvastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg of probucol and about 10 mg of rosuvastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 10 mg of rosuvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 10 mg of rosuvastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 5 mg of rosuvastatin. In preferred embodiments, the content of probucol in the oral unit dosage form can be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of rosuvastatin can be about 2.5 mg to about 20 mg, or about 5 mg to about 10 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 0.5 mg to about 4 mg, about 1 mg to about 4 mg of pitavastatin. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 0.5 mg to about 4 mg, about 1 mg to about 4 mg of pitavastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 1 mg to about 2 mg of pitavastatin. In some embodiments, the oral unit dosage form contains about 62.5 mg of probucol and about 2 mg of pitavastatin. In some embodiments, the oral unit dosage form contains about 125 mg of probucol and about 2 mg of pitavastatin. In some embodiments, the oral unit dosage form contains about 250 mg of probucol and about 2 mg of pitavastatin. In preferred embodiments, in the oral unit dosage form, the content of probucol may be about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg; the content of pitavastatin may be about 0.5 mg to about 4 mg, about 1 mg to about 4 mg, or about 2 mg to about 4 mg. In a third aspect, the present invention provides a drug kit comprising probucol and a statin; in particular, the active ingredients contained in the drug kit are probucol and a statin. In one embodiment of this aspect, the medicine box comprises a first pharmaceutical composition containing probucol and a second pharmaceutical composition containing a statin. In the present invention, the amount of probucol in the first pharmaceutical composition contained in the medicine box and the amount of statins in the second pharmaceutical composition contained in the medicine box are such amounts: the amount of probucol is 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the "Guidelines for Chinese Blood Lipid Management (2023)", wherein a and b are integers from 1 to 16, and a≤b, and the amount of statins is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the "Guidelines for Chinese Blood Lipid Management (2023)", wherein c and d are integers from 1 to 16, and c≤d, for example, c≤d / 2. With the development of medicine and changes in human physique, if new conventional daily doses of probucol for lowering cholesterol and conventional daily doses of statins for lowering cholesterol are updated or proposed in the future "Guidelines for Chinese Blood Lipid Management" or other authoritative guidelines, the amount of probucol shall be 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein a and b are integers of 1-16 and a≤b, and the amount of statins shall be c / d of the maximum daily dose of statins for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein c and d are integers of 1-16 and c≤d, for example, c≤d / 2. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 10 mg to about 1000 mg, and the second pharmaceutical composition comprises a statin in an amount of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 20 mg to about 400 mg, and the second pharmaceutical composition comprises a statin in an amount of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises a statin in an amount of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises a statin in an amount of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg, or about 2 mg to about 80 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises lovastatin in an amount of about 10 mg to about 20 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises lovastatin in an amount of about 5 mg to about 40 mg, or about 10 mg to about 20 mg. In some embodiments, the weight ratio of probucol to lovastatin is about 0.25:1 to 25:1, for example, about 0.25:1, 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15 ... .625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, or 40:1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 125 mg of probucol and the second pharmaceutical composition comprises about 20 mg of lovastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 10 mg of lovastatin. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises pravastatin in an amount of about 10 mg to about 40 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises pravastatin in an amount of about 7.5 mg to about 30 mg, or about 15 mg. In some embodiments, the weight ratio of probucol to pravastatin is about 0.25:1 to 25:1, for example, about 0.25:1, 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 25:3, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 15 mg of pravastatin. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises simvastatin in an amount of about 10 mg to about 40 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises simvastatin in an amount of about 5 mg to about 80 mg, or about 5 mg to about 40 mg, or about 10 mg to about 80 mg, or about 20 mg to about 40 mg. In some embodiments, the weight ratio of probucol to simvastatin is about 0.25:1 to 25:1, for example, about 0.25:1, 0.5:1, 1:1, 25:16, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 62.5 mg of probucol and the second pharmaceutical composition comprises about 40 mg of simvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 125 mg of probucol and the second pharmaceutical composition comprises about 40 mg of simvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 20 mg of simvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 40 mg of simvastatin. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises fluvastatin in an amount of about 20 mg to about 40 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises fluvastatin in an amount of about 10 mg to about 80 mg, or about 20 mg to about 80 mg, or about 40 mg to about 80 mg. In some embodiments, the weight ratio of probucol to fluvastatin is about 0.25:1 to 25:1, for example, about 0.25:1, 0.5:1, 1:1, 25:16, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 125 mg of probucol and the second pharmaceutical composition comprises about 40 mg of fluvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 125 mg of probucol and the second pharmaceutical composition comprises about 80 mg of fluvastatin. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises atorvastatin in an amount of about 10 mg to about 40 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises atorvastatin in an amount of about 5 mg to about 40 mg, or about 5 mg to about 20 mg, or about 10 mg to about 20 mg. In some embodiments, the weight ratio of probucol to atorvastatin is about 0.5:1 to 25:1, e.g., 0.5:1, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, or 25:1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 62.5 mg of probucol and the second pharmaceutical composition comprises about 20 mg of atorvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 125 mg of probucol and the second pharmaceutical composition comprises about 20 mg of atorvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 10 mg of atorvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 20 mg of atorvastatin. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises rosuvastatin in an amount of about 5 mg to about 40 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises rosuvastatin in an amount of about 2.5 mg to about 20 mg, or about 5 mg to about 10 mg. In some embodiments, the weight ratio of probucol to rosuvastatin is about 1:1 to 60:1, for example, 1:1, 2:1, 3:1, 3.125:1, 4:1, 5:1, 6:1, 6.25:1, 7:1, 8:1, 9:1, 9.375:1, 10:1, 11:1, 12:1, 12.5:1, 13:1, 14:1, 15:1, 15.625:1, 16:1, 17:1, 18:1, 19:25:1, 20:25:1, 21:25:1, 22:25:1, 23:25:1, 24:25:1, 25:25:1, 26:25:1, 27:25:1, 28:25:1, 29:35:1, 30:35:1 1, 18:1, 18.75:1, 19:1, 20:1, 21:1, 21.875:1, 22:1, 23:1, 24:1, 25:1, 26:1, 28:1, 30:1, 32:1, 34:1, 36:1, 38:1, 40:1, 42:1, 44:1, 46:1, 48:1, 50:1, 52:1, 54:1, 56:1, 58:1, or 60:1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 62.5 mg of probucol and the second pharmaceutical composition comprises about 10 mg of rosuvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 125 mg of probucol and the second pharmaceutical composition comprises about 10 mg of rosuvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 5 mg of rosuvastatin. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 10 mg of rosuvastatin. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises pitavastatin in an amount of about 1 mg to about 2 mg. In a preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the second pharmaceutical composition comprises pitavastatin in an amount of about 0.5 mg to about 4 mg, about 1 mg to about 4 mg, or about 2 mg to about 4 mg. In some embodiments, the weight ratio of probucol to pitavastatin is about 10: 1 to 250: 1, for example, about 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1, 100: 1, 125: 1, 150: 1, 200: 1, or 250: 1. In some preferred embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises about 250 mg of probucol and the second pharmaceutical composition comprises about 2 mg of pitavastatin. In another embodiment of the third aspect, probucol and statins are provided as a single composition in a kit. In the present invention, the amount of probucol and the amount of statin contained in the single composition in the kit are such that the amount of probucol is 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein a and b are integers from 1 to 16, and a≤b, and the amount of statin is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein c and d are integers from 1 to 16, and c≤d, for example, c≤d / 2. With the development of medicine and changes in human physique, if a new conventional daily dose of probucol for lowering cholesterol and a new conventional daily dose of statins for lowering cholesterol are updated or proposed in the future "Guidelines for Chinese Blood Lipid Management" or other authoritative guidelines, the amount of probucol is 3a / 4b or 5a / 16b or a / 2b of the maximum daily dose of probucol for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein a and b are integers from 1 to 16, and a≤b, and the amount of statins is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the updated "Guidelines for Chinese Blood Lipid Management", wherein c and d are integers from 1 to 16, and c≤d, for example, c≤d / 2. In some embodiments, the kit comprises a pharmaceutical composition comprising probucol, a statin, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is an oral unit dosage form. In some embodiments, the pharmaceutical composition is an oral unit dosage form comprising probucol or a pharmaceutically acceptable salt thereof in an amount of about 10 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 40 mg to about 400 mg, about 60 mg to about 250 mg, about 31.25 mg, about 62.5 mg, about 125 mg, about 187.5 mg, about 250 mg, about 312.5 mg, or about 375 mg and a statin in an amount of about 0.5 mg to about 80 mg, about 1 mg to about 80 mg, about 5 mg to about 80 mg, about 5 mg to about 40 mg, about 10 mg to about 20 mg, or about 1 mg to about 5 mg. In preferred embodiments, the oral unit dosage form comprises about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, of probucol or a pharmaceutically acceptable salt thereof; and about 0.5 mg to about 80 mg, about 1 mg to about 80 mg, or about 2 mg to about 80 mg of a statin. In some embodiments, the pharmaceutical composition is an oral unit dosage form, and the oral unit dosage form is as defined in the second aspect above. In a preferred embodiment, the oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg, of probucol or a pharmaceutically acceptable salt thereof; and from about 5 mg to about 40 mg, or from about 10 mg to about 20 mg, of lovastatin; for example, the oral unit dosage form comprises about 125 mg of probucol or a pharmaceutically acceptable salt thereof; and about 20 mg of lovastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 10 mg of lovastatin; or The oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg, of probucol or a pharmaceutically acceptable salt thereof; and from about 5 mg to about 40 mg, or from about 7.5 mg to about 30 mg, or about 15 mg of pravastatin; for example, the oral unit dosage form comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 15 mg of pravastatin; or The oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and from about 5 mg to about 80 mg, or from about 5 mg to about 40 mg, or from about 10 mg to about 80 mg, or from about 20 mg to about 40 mg of simvastatin; for example, the oral unit dosage form comprises about 62.5 mg of probucol or a pharmaceutically acceptable salt thereof; and about 40 mg of simvastatin, or comprises about 125 mg of probucol or a pharmaceutically acceptable salt thereof; and about 40 mg of simvastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 20 mg of simvastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 40 mg of simvastatin; or The oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and from about 10 mg to about 80 mg, or from about 20 mg to about 80 mg, or from about 40 mg to about 80 mg of fluvastatin; for example, the oral unit dosage form comprises about 125 mg of probucol or a pharmaceutically acceptable salt thereof; and about 40 mg of fluvastatin, or comprises about 125 mg of probucol or a pharmaceutically acceptable salt thereof; and about 80 mg of fluvastatin; or The oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and from about 5 mg to about 40 mg, or from about 5 mg to about 20 mg, or from about 10 mg to about 20 mg of atorvastatin; for example, the oral unit dosage form comprises about 62.5 mg of probucol or a pharmaceutically acceptable salt thereof; and about 20 mg of atorvastatin, or comprises about 125 mg of probucol or a pharmaceutically acceptable salt thereof; and about 20 mg of atorvastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 10 mg of atorvastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 20 mg of atorvastatin; or The oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg, of probucol or a pharmaceutically acceptable salt thereof; and from about 2.5 mg to about 20 mg, or from about 5 mg to about 10 mg, of rosuvastatin; for example, the oral unit dosage form comprises from about 62.5 mg of probucol or a pharmaceutically acceptable salt thereof; and about 10 mg of rosuvastatin, or comprises about 125 mg of probucol or a pharmaceutically acceptable salt thereof; and about 10 mg of rosuvastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 5 mg of rosuvastatin, or comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 10 mg of rosuvastatin; or The oral unit dosage form comprises from about 62.5 mg to about 250 mg, or from about 125 mg to about 250 mg, of probucol or a pharmaceutically acceptable salt thereof; and from about 0.5 mg to about 4 mg, from about 1 mg to about 4 mg, or from about 2 mg to about 4 mg of pitavastatin; for example, the oral unit dosage form comprises about 250 mg of probucol or a pharmaceutically acceptable salt thereof; and about 2 mg of pitavastatin. In some embodiments, the kit optionally includes written material, such as instructions describing the pharmacological activity of the composition, dosage and regimen, side effects, drug interactions, and the like. In one embodiment of this aspect, the amount of probucol and the amount of statin contained in the kit are as described in any one of the above embodiments, and In the drug kit, probucol and the statin are provided in the form of a single composition in the drug kit; or the drug kit comprises one or more identical drug units isolated from the external environment, each drug unit comprising a first drug composition containing probucol and a second drug composition containing a statin, the first drug composition and the second drug composition are each in an oral unit dosage form, wherein opening of each drug unit exposes the first drug composition and the second drug composition to the external environment at the same time. In one embodiment of this aspect, the medicine kit comprises one or more identical medicine units isolated from the external environment, and one, two, or three medicine units can be opened simultaneously for each administration, each medicine unit comprising probucol and a statin according to the present invention, and opening each medicine unit can expose the first pharmaceutical composition and the second pharmaceutical composition to the external environment simultaneously. In a fourth aspect, the present invention provides the use of probucol and a statin in the preparation of a medicament for treating hyperlipidemia (particularly severe hypertriglyceridemia). In particular, the probucol and the statin are in the form of the probucol and statin (including lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin) described in the technical solutions provided in the first, second, or third aspects. In a fifth aspect, the present invention provides a pharmaceutical combination comprising probucol and a statin, or a pharmaceutical composition comprising probucol, a statin, and a pharmaceutically acceptable carrier, or a kit comprising probucol and a statin, for treating hyperlipidemia (particularly severe hypertriglyceridemia). In particular, the pharmaceutical combination comprising probucol and a statin, or the pharmaceutical composition comprising probucol, a statin, and a pharmaceutically acceptable carrier, or the kit comprising probucol and a statin correspond to the pharmaceutical combination, pharmaceutical composition, and kit provided in the first, second, or third aspect, respectively. In a sixth aspect, the present invention provides a method for treating hyperlipidemia (particularly severe hypertriglyceridemia) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of probucol and a therapeutically effective amount of a statin. In particular, the probucol and the statin are in the form of the probucol and statin (including lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin, pitavastatin) described in the technical solutions provided in the first, second, or third aspects. In some embodiments, the hyperlipidemia is hypertriglyceridemia. In some embodiments, the hyperlipidemia is severe hypertriglyceridemia. In some embodiments, the hyperlipidemia is hypercholesterolemia. In some embodiments, the hyperlipidemia is fibrate-intolerant or non-responsive hyperlipidemia, particularly severe hypertriglyceridemia. In some embodiments, the hyperlipidemia is hyperlipidemia that is ineffective or ineffective in treatment with statins and / or red yeast rice, particularly severe hypertriglyceridemia. In some embodiments, the hyperlipidemia is a combination of hypertriglyceridemia and hypercholesterolemia. In some embodiments, the hyperlipidemia is a combination of severe hypertriglyceridemia and hypercholesterolemia. In some embodiments, probucol and the statin are administered to the subject orally. In some embodiments, probucol and the statin are administered orally to the subject in the form of tablets. In some embodiments, probucol and the statin are administered orally to the subject in the form of capsules. In some embodiments, probucol is administered in a daily dose of about 20 mg to about 400 mg. In some embodiments, probucol is administered in a daily dose of about 40 mg to about 400 mg. In some embodiments, probucol is administered at a daily dose of about 31.25 mg. In some embodiments, probucol is administered at a daily dose of about 62.5 mg. In some embodiments, probucol is administered at a daily dose of about 125 mg. In some embodiments, probucol is administered at a daily dose of about 187.5 mg. In some embodiments, probucol is administered at a daily dose of about 250 mg. In some embodiments, probucol is administered at a daily dose of about 312.5 mg. In some embodiments, probucol is administered at a daily dose of about 375 mg. In some embodiments, the statin is administered in a daily dose of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg. In some embodiments, lovastatin is administered in a daily dose of about 5 mg to about 40 mg, preferably about 10 mg to about 40 mg, more preferably about 10 mg or about 20 mg. In some embodiments, pravastatin is administered in a daily dose of about 5 mg to about 40 mg, preferably about 10 mg to about 40 mg, and more preferably about 15 mg. In some embodiments, simvastatin is administered in a daily dose of about 2.5 mg to about 40 mg, preferably about 10 mg to about 40 mg, more preferably about 20 mg or about 40 mg. In some embodiments, fluvastatin is administered in a daily dose of about 10 mg to about 80 mg, preferably about 40 mg to about 80 mg, more preferably about 40 mg or about 80 mg. In some embodiments, atorvastatin is administered in a daily dose of about 5 mg to about 80 mg, preferably about 10 mg to about 40 mg, more preferably about 10 mg or about 20 mg. In some embodiments, rosuvastatin is administered in a daily dose of about 2.5 mg to about 20 mg, preferably about 5 mg to about 20 mg, more preferably about 5 mg or about 10 mg. In some embodiments, pitavastatin is administered at a daily dose of about 0.5 mg to about 4 mg, about 1 mg to about 4 mg, preferably about 2 mg to about 4 mg, more preferably about 2 mg or about 4 mg. In a preferred embodiment, probucol is administered at a daily dose of about 62.5 mg to about 250 mg, or about 125 mg to about 250 mg, and the statin is administered at a daily dose of about 0.5 mg to about 80 mg, or about 1 mg to about 80 mg, or about 2 mg to about 80 mg; for example, lovastatin is administered at a daily dose of about 5 mg to about 40 mg, or about 10 mg to about 20 mg, or pravastatin is administered at a daily dose of about 7.5 mg to about 30 mg, or about 15 mg, or simvastatin is administered at a daily dose of about 10 mg to about 40 mg. or about 80 mg, or about 20 mg to about 40 mg per day, or fluvastatin is administered at a daily dose of about 20 mg to about 80 mg, or about 40 mg to about 80 mg per day, or atorvastatin is administered at a daily dose of about 5 mg to about 40 mg, or about 10 mg to about 20 mg per day, or rosuvastatin is administered at a daily dose of about 2.5 mg to about 20 mg, or about 5 mg to about 10 mg per day, or pitavastatin is administered at a daily dose of about 0.5 mg to about 4 mg, about 1 mg to about 4 mg, or about 2 mg to about 4 mg per day. In some embodiments, probucol and statins are administered to the subject simultaneously. In some embodiments, probucol and statins are each administered to the subject simultaneously with a separate formulation, with an administration interval of less than 30 minutes, such as less than 15 minutes, less than 10 minutes, less than 5 minutes, or less than 1 minute. In some embodiments, the daily dose of probucol and statins is administered to the subject in a single or multiple doses. In some embodiments, probucol and statins are administered to the subject simultaneously once a day (QD), preferably simultaneously before going to bed. In some embodiments, probucol and statins are administered to the subject twice a day (BID), preferably twice a day after a meal. In some embodiments, probucol and statins are administered simultaneously for no less than 7 days. In some embodiments, probucol and statins are administered simultaneously for about 14 days. In some embodiments, probucol and statins are administered simultaneously for about 28 days. In some embodiments, probucol and the statin are administered concurrently for about 56 days. In some embodiments, probucol and the statin are administered chronically. In a first aspect, the present invention also provides a pharmaceutical combination comprising probucol and red yeast rice. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of red yeast rice. In some embodiments, the therapeutically effective amount of probucol is from about 10 mg to about 1000 mg. In some embodiments, the therapeutically effective amount of probucol is from about 20 mg to about 800 mg. In some embodiments, the therapeutically effective amount of probucol is from about 20 mg to about 400 mg. In some embodiments, the therapeutically effective amount of probucol is from about 40 mg to about 400 mg. In some embodiments, the therapeutically effective amount of probucol is from about 62.5 mg to about 375 mg. In some embodiments, the therapeutically effective amount of probucol is from about 62.5 mg to about 250 mg. In some embodiments, the therapeutically effective amount of probucol is about 20 mg, 25 mg, 30 mg, 31.25 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 62.5 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 187.5 mg, 190 mg, 195 mg, 200 mg. , 205mg, 210mg, 215mg, 220mg, 225mg, 230mg, 235mg, 240mg, 245mg, 250mg, 255mg, 260mg, 265mg, 270mg, 275mg, 280mg, 285mg, 290mg, 295mg, 300mg, 305mg, 310mg, 312.5mg, 315mg, 320mg, 325mg, 330mg, 335mg, 340mg, 345mg, 350mg, 355mg, 360mg, 365mg, 370mg, 375mg, 380mg, 385mg, 390mg, 395mg or 400mg. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of red yeast rice. In some embodiments, the therapeutically effective amount of red yeast rice is about 2 mg to about 50 mg. In some embodiments, the therapeutically effective amount of red yeast rice is about 3 mg to about 40 mg. In some embodiments, the therapeutically effective amount of red yeast rice is about 5 mg to about 35 mg. In some embodiments, the therapeutically effective amount of red yeast rice is about 7 to about 30 mg. In some embodiments, the therapeutically effective amount of red yeast rice is about 7 to about 20 mg. In some embodiments, the therapeutically effective amount of red yeast rice is, for example, about 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 7.5 mg, 8 mg, 8.3 mg, 9 mg, 10 mg, 10.5 mg, 11 mg, 12 mg, 12.5 mg, 13 mg, 14 mg, 15 mg, 16 mg, 16.6 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22mg, 23mg, 24mg, 24.9mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 33.2mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg or 50mg. Any weight of the therapeutically effective amount of probucol within the above range and any weight of the therapeutically effective amount of red yeast rice within the above range may constitute the pharmaceutical composition mentioned in the present invention. In some embodiments, the pharmaceutical combination comprises a therapeutically effective amount of probucol and a therapeutically effective amount of red yeast rice, wherein the therapeutically effective amount ratio of probucol to red yeast rice is about (1-100): 1. In some embodiments, the therapeutically effective amount ratio of probucol to red yeast rice is about (1.5-75): 1. In some embodiments, the therapeutically effective amount ratio of probucol to red yeast rice is about (5-40): 1. In some embodiments, the therapeutically effective amount ratio of probucol to red yeast rice is about (6-20): 1. In some embodiments, the therapeutically effective amount ratio of probucol to red yeast rice is about (7-15): 1. In some embodiments, the therapeutically effective amount ratio of probucol to red yeast rice is about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, or 40:1. In some embodiments, the pharmaceutical combination comprises about 20 to about 800 mg of probucol and about 2 to about 50 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 2 to about 50 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 20 to about 400 mg of probucol and about 3 to about 40 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 40 to about 400 mg of probucol and about 5 to about 35 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 to about 375 mg of probucol and about 5 to about 35 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 to about 250 mg of probucol and about 7 to about 30 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 7 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 8 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 10 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 12 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 17 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 62.5 mg of probucol and about 20 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 7 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 8 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 10 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 12 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 17 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 125 mg of probucol and about 20 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 7 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 8 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 10 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 12 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 17 mg of red yeast rice. In some embodiments, the pharmaceutical combination comprises about 250 mg of probucol and about 20 mg of red yeast rice. In some embodiments, probucol and red yeast rice are provided in separate preparations. In some embodiments, probucol is provided in the form of probucol tablets. In some embodiments, red yeast rice is provided in the form of tablets (including dispersible tablets), granules, capsules or pills, preferably tablets or capsules. The tablets, granules, capsules or pills contain a certain amount of red yeast rice so that the tablets or capsules contain 0.2-5wt% of monacolin K, wherein the weight ratio of closed-loop monacolin K to open-loop monacolin K can be (100: 1) to (1: 100), for example (50: 1) to (1: 50), or (15: 1) to (1: 15), or (1: 1) to (1: 15). The tablets or capsules can be provided in the form of the Chinese patent medicine Zhibitai capsules, Zhibituo capsules, Zhibitai tablets, Xuezhikang capsules, and Xuezhikang tablets. In some embodiments, probucol and red yeast rice are provided in a single composition, for example, in a single tablet, capsule, granule, pellet, or micropill. In a second aspect, the present invention also provides a pharmaceutical composition comprising probucol, red yeast rice and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises about 0.1% to 99.5% by weight of the active ingredient (i.e., probucol and red yeast rice), preferably about 0.5% to 99.5% by weight, more preferably about 1% to 50% by weight, for example, about 1%, about 1.5%, about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or about 50% by weight of the active ingredient. In some embodiments, the weight ratio of probucol to red yeast rice in the pharmaceutical composition is about (1-100): 1, for example, about (1.5-75): 1, (5-40): 1, (6-20): 1, (7-15): 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11: 1, 12: 1, 13: 1, 14: 1, 15: 1, 16: 1, 17: 1, 18: 1, 19: 1, 20: 1, 25: 1, 30: 1, 35: 1 or 40: 1. The remainder of the pharmaceutical composition is a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises two, three or more pharmaceutically acceptable carriers. Examples of the pharmaceutically acceptable carrier include, but are not limited to, conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, lubricants, colorants, fragrances, absorption enhancers, surfactants, adsorption carriers, etc. in the pharmaceutical field. In some embodiments, the pharmaceutical composition is prepared into a pharmaceutically acceptable dosage form. For example, in some embodiments, probucol and red yeast rice (e.g., red yeast rice extract) can be mixed with one or more pharmaceutically acceptable carriers and prepared into a pharmaceutically acceptable dosage form according to conventional production methods in the pharmaceutical field. Examples of the pharmaceutically acceptable dosage form include, but are not limited to, conventional solid dosage forms in the pharmaceutical field (such as, but not limited to, tablets (including ordinary tablets, coated tablets, chewable tablets, enteric-coated tablets, sustained-release tablets, controlled-release tablets, orally disintegrating tablets, dispersible tablets, effervescent tablets, etc.), capsules (including hard capsules, soft capsules, enteric-coated capsules, sustained-release capsules, controlled-release capsules, etc.), granules (including soluble granules, suspension granules, enteric-coated granules, sustained-release granules, controlled-release granules, effervescent granules, etc.), pills, micropills, etc.), liquid dosage forms (such as, but not limited to, solutions, syrups, suspensions, emulsions, etc.), etc. In some embodiments, the pharmaceutical composition is in a unit dosage form suitable for oral administration. For example, a tablet, capsule, or granule, each containing a predetermined amount of active ingredient. In some embodiments, the pharmaceutical composition is a capsule. In some embodiments, the pharmaceutical composition is a tablet. In some embodiments, the pharmaceutical composition is a chewable tablet. In some embodiments, the pharmaceutical composition is a multi-layer tablet, such as a bi-layer tablet, wherein the first layer contains probucol and a pharmaceutically acceptable carrier, and the second layer contains red yeast rice and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is an oral unit dosage form containing a therapeutically effective amount of probucol and red yeast rice. In some embodiments, the content of probucol in the oral unit dosage form can vary in the range of about 10 mg to about 1000 mg, for example, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 40 mg to about 400 mg, about 62.5 mg to about 375 mg, about 62.5 mg to about 250 mg, about 31.25 mg, about 62.5 mg, about 125 mg, about 187.5 mg, about 250 mg, about 312.5 mg or about 375 mg. In some embodiments, the content of red yeast rice in the oral unit dosage form can vary in the range of about 2 mg to about 50 mg, for example, about 3 mg to about 40 mg, about 5 mg to about 35 mg, about 7 mg to about 30 mg or about 7 mg to about 20 mg. In some embodiments, the oral unit dosage form contains about 20 mg to about 800 mg of probucol and about 2 mg to about 50 mg of red yeast rice. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 2 mg to about 50 mg of red yeast rice. In some embodiments, the oral unit dosage form contains about 20 mg to about 400 mg of probucol and about 3 mg to about 40 mg of red yeast rice. In some embodiments, the oral unit dosage form contains about 40 mg to about 400 mg of probucol and about 5 mg to about 35 mg of red yeast rice. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 375 mg of probucol and about 5 mg to about 35 mg of red yeast rice. In some embodiments, the oral unit dosage form contains about 62.5 mg to about 250 mg of probucol and about 7 mg to about 30 mg of red yeast rice. In some embodiments, the oral unit dosage form contains about 31.25 mg, about 62.5 mg, about 125 mg, about 187.5 mg, about 250 mg, about 312.5 mg, or about 375 mg of probucol and about 2.5 mg, about 3.5 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 10 mg, about 12 mg, about 16 mg, or about 20 mg of red yeast rice. In a third aspect, the present invention also provides a pharmaceutical kit comprising a first pharmaceutical composition comprising probucol and a second pharmaceutical composition comprising red yeast rice. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 10 mg to about 1000 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 2 mg to about 50 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 20 mg to about 800 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 2 mg to about 50 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 20 mg to about 400 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 2 mg to about 50 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 20 mg to about 400 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 3 mg to about 40 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 40 mg to about 400 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 5 mg to about 35 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 375 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 5 mg to about 35 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 62.5 mg to about 250 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 7 mg to about 30 mg. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form, wherein the first pharmaceutical composition comprises probucol in an amount of about 31.25 mg, about 62.5 mg, about 125 mg, about 187.5 mg, about 250 mg, about 312.5 mg, or about 375 mg, and the second pharmaceutical composition comprises red yeast rice in an amount of about 2.5 mg, about 3.5 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 10 mg, about 12 mg, about 16 mg, or about 20 mg. In some embodiments, probucol and red yeast rice are provided as a single composition in a medicine kit. In some embodiments, the medicine kit comprises a pharmaceutical composition comprising probucol, red yeast rice and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is an oral unit dosage form. In some embodiments, the pharmaceutical composition is an oral unit dosage form comprising about 10 mg to about 1000 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about 40 mg to about 400 mg, about 62.5 mg to about 375 mg or about 62.5 mg to about 250 mg of probucol, and about 2 mg to about 50 mg, about 3 mg to about 40 mg, about 5 mg to about 35 mg, about 7 mg to about 30 mg or about 7 mg to about 20 mg of red yeast rice. In some embodiments, the pharmaceutical composition is an oral unit dosage form, and the oral unit dosage form is as defined in the aforementioned second aspect. In some embodiments, the kit optionally includes written material, such as instructions describing the pharmacological activity of the composition, dosage and regimen, side effects, drug interactions, and the like. In a fourth aspect, the present invention also provides use of probucol and red yeast rice in preparing a medicament for treating hyperlipidemia. In a fifth aspect, the present invention further provides a pharmaceutical combination comprising probucol and red yeast rice or a pharmaceutical composition comprising probucol, red yeast rice and a pharmaceutically acceptable carrier, for use in treating hyperlipidemia. In a sixth aspect, the present invention also provides a method for treating hyperlipidemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of probucol and a therapeutically effective amount of red yeast rice. In some embodiments, the hyperlipidemia is hypertriglyceridemia. In some embodiments, the hyperlipidemia is severe hypertriglyceridemia. In some embodiments, the hyperlipidemia is (severe) hypercholesterolemia. In some embodiments, the hyperlipidemia is fibrate-intolerant or non-responsive hyperlipidemia. In some embodiments, the hyperlipidemia is hyperlipidemia that is ineffective or ineffectively treated with statins and / or red yeast rice. In some embodiments, probucol and red yeast rice are administered to a subject orally. In some embodiments, probucol and red yeast rice are administered orally to a subject in the form of tablets. In some embodiments, probucol and red yeast rice are administered orally to a subject in the form of capsules. In some embodiments, probucol is administered orally to a subject in the form of tablets and red yeast rice is administered orally to a subject in the form of capsules. In some embodiments, probucol is administered orally to a subject in the form of capsules and red yeast rice is administered orally to a subject in the form of tablets. In some embodiments, probucol is administered orally to a subject in the form of granules and red yeast rice is administered orally to a subject in the form of tablets. In some embodiments, probucol is administered at a daily dose of about 20 mg to about 400 mg. In some embodiments, probucol is administered at a daily dose of about 31.25 mg to about 375 mg. In some embodiments, probucol is administered at a daily dose of about 31.25 mg to about 375 mg. In some embodiments, probucol is administered at a daily dose of about 62.5 mg to about 250 mg. In some embodiments, probucol is administered at a daily dose of about 31.25 mg, about 62.5 mg, about 125 mg, about 187.5 mg, about 250 mg, about 312.5 mg, or about 375 mg. In some embodiments, red yeast rice is administered at a daily dose of about 2 mg to about 50 mg. In some embodiments, red yeast rice is administered at a daily dose of about 3 mg to about 40 mg. In some embodiments, red yeast rice is administered at a daily dose of about 5 mg to about 35 mg. In some embodiments, red yeast rice is administered at a daily dose of about 7 mg to about 30 mg. In some embodiments, red yeast rice is administered at a daily dose of about 7 mg to about 20 mg. In some embodiments, red yeast rice is administered at a daily dose of about 2.5 mg, about 3.5 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 10 mg, about 12 mg, about 17 mg, or about 20 mg. In some embodiments, probucol and red yeast rice are administered to the subject simultaneously. In some embodiments, probucol and red yeast rice are each administered to the subject simultaneously with a separate formulation, with an administration interval of less than 30 minutes, such as less than 15 minutes, less than 10 minutes, less than 5 minutes, or less than 1 minute. In some embodiments, the daily dose of probucol and red yeast rice is administered to the subject in a single or multiple doses. In some embodiments, probucol and red yeast rice are administered to the subject once a day (QD) simultaneously. In some embodiments, probucol and red yeast rice are administered to the subject twice a day (BID) simultaneously. In some embodiments, probucol and red yeast rice are administered simultaneously for no less than 7 days. In some embodiments, probucol and red yeast rice are administered simultaneously for about 14 days. In some embodiments, probucol and red yeast rice are administered simultaneously for about 28 days. In some embodiments, probucol and red yeast rice are administered simultaneously for about 56 days. In some embodiments, probucol and red yeast rice are administered for a long term. The beneficial effects of the present invention include the following aspects: (1) The present inventors surprisingly discovered that the combination of probucol and statins can produce a synergistic effect in the treatment of severe hypertriglyceridemia, hyperlipidemia that is intolerant to or unresponsive to fibrates, or hyperlipidemia that is ineffective or ineffective with statins and / or red yeast rice: probucol used in an amount lower than its conventional dose can promote a greater therapeutic effect of statins, breaking through the "6% statin efficacy effect" and achieving unexpectedly high therapeutic effects even when statins are used at medium or low doses. This not only indirectly expands the dosage range of statins, but also discovers a new way to tolerably lower triglycerides in severe hypertriglyceridemia; (2) The present invention has produced unexpected effects in the treatment of severe hypertriglyceridemia. Probucol alone has no triglyceride-lowering effect, and statins / red yeast rice alone do not treat severe hypertriglyceridemia. The present invention uses a small dose of probucol (e.g., 12.5%-25% of the conventional dose) in combination with statins or red yeast rice (which can be conventional doses or medium-to-low doses) to quickly and effectively lower triglycerides in severe hypertriglyceridemia, with a reduction of more than 70%, which is no less effective than first-line fibrates (60%). This solves the clinical problem of having no alternative effective drugs when myolysis and liver and kidney function abnormalities occur after fibrate treatment. In addition, compared with drugs for treating severe hypertriglyceridemia, such as fibrates and high-dose fish oil that increase low-density lipoprotein, the combination can lower low-density lipoprotein-C, thereby providing a new and more effective treatment option for treating severe hypertriglyceridemia. (3) Current treatments for severe hypertriglyceridemia, such as fibrates and high-dose fish oil, increase low-density lipoprotein (LDL). If severe hypertriglyceridemia is complicated by cardiovascular risk, fibrates must be combined with statins for treatment, but the combined treatment has significant side effects. The drug combination of the present invention can significantly reduce triglycerides in severe hypertriglyceridemia and further reduce cholesterol and LDL-C. It is a broad-spectrum lipid-lowering drug that is suitable for both hypertriglyceridemia and / or hypercholesterolemia and can reduce cardiovascular risk, thus resolving a clinical problem. (4) For patients whose LDL-C levels do not meet the target after treatment with red yeast rice / statins, the drug combination of the present invention can further reduce cholesterol (e.g., 26% / 32%) and low-density lipoprotein-C (e.g., 28% / 38%), which is superior to the statin combined with ezetimibe recommended by the lipid management guidelines, thereby reducing the risk of cardiovascular disease; (5) The present invention can significantly reduce triglycerides in severe hypertriglyceridemia and further reduce cholesterol and low-density lipoprotein-C. It is a broad-spectrum lipid-lowering drug and is suitable for hypertriglyceridemia and / or hypercholesterolemia. (6) In the present invention, probucol is used at an amount lower than its conventional dose (e.g., 6.25% or 12.5% of the conventional dose), and statins are used at low to medium doses, which can approach or exceed the LDL-C lowering amplitude of the corresponding maximum dose of statins, making the drug combination more tolerable, with lower toxic side effects and fewer adverse reactions to long-term medication; (7) In the present invention, probucol is used in an amount lower than its conventional dose (e.g., 25% of the conventional dose), and red yeast rice contains natural statins with less muscle toxicity and liver and kidney damage, which makes the drug combination better tolerated, has lower toxic side effects, and has fewer adverse reactions to long-term medication; (8) In the present invention, the drug combination of probucol and statins can quickly take effect and reduce TG, TC and LDL-C to satisfactory levels within a shorter treatment period; (9) The present inventors have found that the simultaneous administration of probucol and statins / red yeast rice produces an unexpected technical effect. If statins / red yeast rice and probucol are taken separately, or if they are taken together but with an increased dose of probucol, the effect disappears (regardless of the effect of lowering severe hypertriglyceridemia and / or LDL-C). Example The following examples are intended to illustrate the present invention in detail and should not be construed as limiting the scope of the present invention. Example A1: Study on the efficacy of a combination of probucol and statins in the treatment of severe hypertriglyceridemia A total of 29 patients with severe hypertriglyceridemia received probucol and statin combination therapy, including 21 males and 8 females, aged 27-68 years. Before administration, the triglyceride range of patients with severe hypertriglyceridemia was 5.93-21.41 mmol / L, the cholesterol range was 3.46-9.85 mmol / L, and the low-density lipoprotein range was 1.22-4.01 mmol / L. Dosage regimen: Probucol and statins are taken orally as commercially available tablets (which can be taken with water or chewed), once a day, at the same time before bedtime, for an average of 45 days. Treatment Results: After treatment, patients experienced significant decreases in plasma triglycerides, with triglyceride levels dropping by 35-91% and an average of 80%. Cholesterol levels dropped by 20-69% and an average of 41%. Low-density lipoprotein cholesterol levels dropped by 8-58% and an average of 23%. See Table A1 below for detailed results. Table A1 Treatment outcomes of probucol combined with statins in: A: Probucol 62.5 mg + atorvastatin 20 mg, QD; B: Probucol 125 mg + atorvastatin 20 mg, QD; C: probucol 250 mg + atorvastatin 20 mg, QD; D: probucol 250 mg + atorvastatin 10 mg, QD; E: probucol 62.5 mg + rosuvastatin 10 mg, QD; F: probucol 125 mg + rosuvastatin 10 mg, QD; G: probucol 250 mg + rosuvastatin 10 mg, QD; H: probucol 250 mg + rosuvastatin 5 mg, QD; I: probucol 62.5 mg + simvastatin 40 mg, QD; J: probucol 125 mg + simvastatin 40 mg, QD; K: probucol 250 mg + simvastatin 40 mg, QD; L: probucol 250 mg + simvastatin 20 mg, QD; M: probucol 250 mg + pitavastatin 2 mg, QD; N: probucol 125 mg + fluvastatin 80 mg, QD; O: probucol 125 mg + fluvastatin 40 mg, QD; P: probucol 125 mg + lovastatin 20 mg, QD; Q: Probucol 250 mg + Lovastatin 10 mg, QD; R: Probucol 125 mg + Pravastatin 15 mg, QD. The inventors surprisingly found that, at the same probucol dosage, reducing the dosage of the statin compound can actually achieve an increased LDL-C lowering amplitude (probucol 250 mg + atorvastatin 20 mg, QD vs. probucol 250 mg + atorvastatin 10 mg, QD; probucol 250 mg + rosuvastatin 10 mg, QD vs. probucol 250 mg + rosuvastatin 5 mg, QD; and probucol 125 mg + fluvastatin 80 mg, QD vs. probucol 125 mg + fluvastatin 40 mg, QD). Therefore, it is believed that the simultaneous use of probucol and the statin compound produces a synergistic effect. Compared to other drugs for treating severe hypertriglyceridemia, the low-dose drug combination of the present invention significantly lowered triglycerides, outperforming fibrates and high-dose fish oil. Furthermore, unlike fibrates and high-dose fish oil, which increase low-density lipoprotein (LDL) cholesterol, the drug combination of the present invention also simultaneously lowered cholesterol and LDL-C. See Table A2 below. Table A2 Comparison of the efficacy of probucol and statin combination with other drugs for the treatment of severe hypertriglyceridemia Data source: a. Liping's instructions; b.Triglyceride Lowering Drugs.Endotext[Internet].Free Books&Documents.Review. Typical case 1: A 39-year-old male patient had long-term severe hypertriglyceridemia, which induced acute severe necrotizing pancreatitis. After improvement, he took regular fenofibrate treatment (0.2g daily). At 7 months, he developed elevated creatinine, gallstones, and unsatisfactory triglyceride control, reaching 9.78mmol / l. Other treatment options were tried, but they were ineffective and caused triglycerides to rebound to 15.94mmol / l. He switched to a statin-probucol combination: 20mg atorvastatin combined with 125mg probucol every night. After 3 days, triglycerides dropped to 10.34mmol / l, and to 7.25mmol / l after 6 days. Creatinine returned to normal, and muscle enzyme levels did not increase significantly, dropping to 4.14mmol / l on 19 days and to 3.52mmol / l on 26 days. Case 2: A 60-year-old female patient presented with severe hypertriglyceridemia. Probucol 187.5 mg plus rosuvastatin 10 mg were administered daily for 6 weeks. Triglycerides (TG, mmol / L), total cholesterol (TC, mmol / L), and low-density lipoprotein (LDL-C, mmol) decreased from 9.21, 4.65, and 1.70 before treatment to 4.60, 3.49, and 1.32 after treatment, representing decreases of 50%, 25%, and 22%, respectively. Typical case 3: A 30-year-old male patient had triglyceride (TG): 14.62 mmol / L, total cholesterol (TC): 6.84 mmol / L and low-density lipoprotein (LDL-C): 2.20 mmol / L. He took atorvastatin 20 mg + probucol 250 mg together before bedtime. After a follow-up examination 2 weeks later, triglyceride: 2.79 mmol / L, total cholesterol: 4.76 mmol / L and low-density lipoprotein: 1.99 mmol / L. He then took the medicine separately by himself, taking atorvastatin before bedtime and probucol in the afternoon. After 2 weeks, the levels rebounded to triglyceride: 13.30 mmol / L, total cholesterol: 5.97 mmol / L and low-density lipoprotein: 2.02 mmol / L. Typical case 4: Male patient, 35 years old, triglycerides: 11.93mmol / L, total cholesterol: 6.58mmol / L and low-density lipoprotein: 1.85mmol / L, rosuvastatin 5mg + probucol 125mg each time, twice a day, rechecked after 6 weeks, triglycerides: 3.72mmol / L, total cholesterol: 3.54mmol / L and low-density lipoprotein: 1.66mmol / L, then increased the dosage on his own (after reading the instructions, he thought his condition was serious and should be increased), rosuvastatin 5mg + probucol 500mg each time, twice a day, after 8 weeks rebound to triglycerides: 8.91mmol / L, total cholesterol: 4.32mmol / L and low-density lipoprotein: 1.75mmol / L. Example A2: Study on the efficacy of a combination of probucol and statins in the treatment of hypercholesterolemia Treatment targets: Patients who have taken statins for more than half a year and whose cholesterol levels are not up to standard (including patients who have received statin treatment, patients who have received statins combined with cholesterol absorption inhibitors, patients who have received statins combined with PCSK9 monoclonal antibodies, and patients who have received statins combined with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies) are switched to probucol and statin combination treatment. A total of 12 patients with hypercholesterolemia received probucol and statin combination treatment, including 4 males and 8 females, aged 28-78 years. Before medication, the triglyceride range of patients with hypercholesterolemia was 1.3-4.51mmol / L, the cholesterol range was 4.5-7.56mmol / L, and the low-density lipoprotein range was 2.77-4.64mmol / L. Dosage regimen: Probucol and statins are taken orally as commercially available tablets (which can be taken with water or chewed), once a day, at the same time before bedtime, for an average of 3 weeks. Treatment Results: After treatment, patients' plasma cholesterol levels decreased by 25-36% and low-density lipoprotein levels decreased by 25-40%. Specific results are shown in Table A3 below. Table A3 Treatment results of probucol combined with statins in the treatment of hypercholesterolemia in: AA: probucol 62.5 mg + atorvastatin 20 mg; BB: probucol 125 mg + atorvastatin 20 mg; CC: probucol 250 mg + simvastatin 40 mg; DD: probucol 250 mg + atorvastatin 20 mg; EE: probucol 250 mg + rosuvastatin 10 mg; FF: probucol 125 mg + rosuvastatin 10 mg. Comparison of efficacy with other drugs for treating hypercholesterolemia: According to the 2023 Chinese Guidelines for Lipid Management, when LDL-C levels are not meeting target after statin treatment, the combination of statins and ezetimibe can further reduce LDL-C levels by 18-20%. The drug combination of the present invention can further reduce LDL-C by 25-40%, with an average further reduction of 38%, which is more effective than the combination of statins and ezetimibe. Furthermore, probucol can be used in low doses, with fewer side effects and greater benefits. Case 1: A 68-year-old male patient with myocardial infarction and stent surgery received rosuvastatin 10 mg at bedtime for 12 weeks, resulting in cholesterol levels of 8.86 mmol / L, triglycerides of 2.61 mmol / L, and LDL-C of 5.54 mmol / L. This was followed by 12 weeks of evolocumab 140 mg subcutaneously every 2 weeks, with cholesterol levels of 6.45 mmol / L, triglycerides of 3.05 mmol / L, and LDL-C of 3.61 mmol / L. Three weeks of combined probucol 125 mg and rosuvastatin 10 mg at bedtime reduced cholesterol levels to 4.62 mmol / L, triglycerides of 1.39 mmol / L, and LDL-C of 2.31 mmol / L. Six weeks of separate treatments reduced cholesterol levels to 6.97 mmol / L, triglycerides of 3.11 mmol / L, and LDL-C of 3.55 mmol / L. Typical case 2: The patient was a 67-year-old female ASCVD patient with cholesterol 13.1mmol / L, LDL-C 8.13mmol / L, and triglycerides 3.60mmol / L. She was advised to take 125mg of probucol and 20mg of atorvastatin daily before bedtime. In fact, the patient took the dosage according to the instructions, taking 20mg of atorvastatin and 500mg of probucol daily before bedtime, 500mg of probucol every morning, 500mg of probucol each time, twice a day. After 12 weeks, the cholesterol was 9.32mmol / L, LDL-C was 5.18mmol / L, and triglycerides were 4.04mmol / L. She resumed the low dose and after 14 weeks, the cholesterol was 4.66mmol / L, LDL-C was 2.25mmol / L, and triglycerides were 2.79mmol / L. Case 3: A 66-year-old male patient with ASCVD, myocardial infarction, and stent surgery received probucol 187.5 mg plus rosuvastatin 10 mg daily for 3 weeks. Results were as follows: Before treatment, LDL-C was 3.19 mmol / L, cholesterol was 5.51 mmol / L, and triglycerides were 2.49 mmol / L. After treatment, LDL-C was 1.00 mmol / L, cholesterol was 2.52 mmol / L, and triglycerides were 1.28 mmol / L, representing decreases of 69%, 54%, and 49%, respectively. Trial results indicate that in the treatment of severe hypertriglyceridemia, the combination of probucol and statins (such as atorvastatin, rosuvastatin, simvastatin, fluvastatin, and lovastatin) can achieve comparable or even greater reductions in triglycerides (TG) at lower probucol doses. Alternatively, a greater reduction in LDL-C can be achieved by maintaining the same statin dose at a lower probucol dose, or by maintaining the same probucol dose at a lower statin dose. Therefore, the combination of low-dose probucol and statins can not only significantly lower TG levels but also expand the therapeutic window of statins. Increasing the probucol dose eliminates its effect on lowering severe hypertriglyceridemia, and even splitting the dose eliminates its effect. This is particularly true for lowering LDL-C, as it defies common sense. Besides being ineffective when used alone, the incremental effect of these two cholesterol-lowering drugs is even poor. Probucol has been marketed since 1977, and numerous studies have examined its combined use both domestically and internationally, but have failed to demonstrate efficacy in treating severe hypertriglyceridemia or lowering LDL-C. This is related to the aforementioned characteristics of the combination and the statin and probucol dosing habits (statins are taken at bedtime, and probucol is taken twice daily, in the morning and afternoon). Example A3: Study on the efficacy of a drug combination of probucol and statins in the treatment of hypercholesterolemia at double the dose Patients: Four patients with hypercholesterolemia received probucol and statin combination therapy, including three males and one female, aged 50-70 years. Dosage regimen: Probucol and statins are administered orally as commercially available tablets (which can be taken with water or chewed) once daily, taken simultaneously at bedtime. Initially, administer the low doses shown in Table A4 for a period of 6 weeks or more, followed by a doubled dose (1.5 or 2 times the original dose) as shown in Table A4 for another period of 5-12 weeks. Results: As shown in Table A4, the trial results demonstrate that, in the treatment of hyperlipidemia, coadministration of probucol with a statin can achieve a significantly greater than 6% reduction in LDL-C when doubling the statin dose, even at low probucol doses. This contradicts the common belief that doubling the statin dose only results in an additional 6% reduction in LDL-C levels. This unexpected result is believed to be due to the coadministration of probucol with a statin. Table A4 Efficacy of probucol combined with statins at doubled doses Example A4: Study on the efficacy of a combination of probucol and statins in the treatment of severe hypercholesterolemia The treatment subjects and dosing regimen are shown in Table A5, wherein both probucol and statins are administered orally in the form of commercially available tablets (which can be taken with water or chewed), once a day, and administered simultaneously before bedtime. Table A5: Treatment outcomes of probucol combined with statins in patients with severe hypercholesterolemia in: GG: probucol 125 mg + simvastatin 40 mg; HH: probucol 250 mg + atorvastatin 20 mg; II: probucol 250 mg + rosuvastatin 10 mg; JJ: probucol 125 mg + rosuvastatin 10 mg. Treatment Results: After treatment, patients' plasma cholesterol levels decreased by 53-66% and low-density lipoprotein levels decreased by 53-73%. See Table A5 for detailed results. Example A5: Other treatment cases of drug combination of probucol and statins Case A1: A 62-year-old female patient with severe hypertriglyceridemia and ASCVD was treated with probucol 312.5 mg and simvastatin 40 mg daily for 2 weeks. Probucol and statins were taken together at bedtime. Case A2: A 50-year-old male patient with ASCVD was treated with probucol 312.5 mg and atorvastatin 20 mg daily for 4 weeks. Probucol and statins were taken together at bedtime. Case A3: A 27-year-old male with a family history of severe hypertriglyceridemia was treated with probucol 125 mg and rosuvastatin 10 mg at bedtime for 3 weeks. Case A4: A 42-year-old male with a family history of severe hypercholesterolemia, coronary heart disease, myocardial infarction, and post-stent surgery. Before lipid-lowering treatment, his LDL-C was 6.09 mmol / L, cholesterol was 8.95 mmol / L, and triglycerides were 2.56 mmol / L. He was treated with rosuvastatin 10 mg combined with evolocumab 140 mg subcutaneously every 2 weeks for more than 4 months, with LDL-C levels of 2.84 mmol / L, cholesterol of 4.50 mmol / L, and triglycerides of 1.3 mmol / L. These levels still did not meet the target, so he was given probucol 125 mg taken at bedtime together with rosuvastatin 10 mg. After 5 weeks, his LDL-C levels were 1.42 mmol / L, cholesterol of 2.82 mmol / L, and triglycerides of 1.11 mmol / L. The treatment results of the above cases A1-A4 are shown in Table A6. Table A6: Efficacy of combined use of probucol in specific cases Example A6: Case of primary hypercholesterolemia treated (QD) with a combination of low-medium dose statin and very low dose probucol 62.5 / 125 mg According to the "Guidelines for Blood Lipid Management in China (2023)", the relationship between the intensity of cholesterol-lowering and the drug and its dosage is that high intensity (daily dose can reduce LDL-C ≥ 50%) requires 40-80 mg of atorvastatin / day, or 20 mg of rosuvastatin / day. The patients in the following cases are patients with primary hypercholesterolemia, who take probucol and statins together before bedtime (QD). The following table shows the efficacy of low- and medium-dose statins (10-20 mg of atorvastatin / day, or 5-10 mg of rosuvastatin / day, or simvastatin 10 mg / day, or fluvastatin 20 mg / day, or pitavastatin 1 mg / day) and very low-dose probucol (62.5-125 mg / day) in the treatment of primary hypercholesterolemia (can reduce LDL-C ≥ 50%). Table A7 Example A7: Case of Probucol and Statins in Combination at Doubled Dose for the Treatment of (QD) Hypercholesterolemia Dosage regimen: Probucol and statins are administered orally as commercially available tablets (which can be taken with water or chewed) once daily, administered simultaneously at bedtime. Initially, administer the low doses shown in Table A8 for a period of time (over six months), followed by a further period of time at the doubled doses shown in Table A8. Results: As shown in Table A8, the trial results indicate that, in the treatment of hyperlipidemia, by co-administering probucol and statins, at a low dose of probucol, when the dose of statins is doubled, a reduction in LDL-C significantly exceeding 6% can be achieved, and LDL-C can be reduced in a shorter period of time. Table A8 Example B1: Study on the efficacy of a drug combination of probucol and red yeast rice in treating severe hypertriglyceridemia. Patients: A total of 32 patients with severe hypertriglyceridemia (23 males and 9 females, aged 26-72 years) received probucol and red yeast rice combination therapy. Their pre-treatment triglyceride levels ranged from 5.75 to 22.02 mmol / l, cholesterol levels ranged from 3.43 to 14.08 mmol / l, and low-density lipoprotein levels ranged from 1.02 to 7.89 mmol / l. Dosage regimen: Probucol is administered orally as commercially available probucol tablets (125 mg / tablet) (can be taken with water or chewed), with a dosage of 62.5-312.5 mg / time, once or twice a day; red yeast rice is administered orally as the following commercially available products (can be taken with water or chewed): Zhibitai capsules (240 mg / tablet, containing approximately 9.1 mg / tablet of monacolin K), with a dosage of 240-480 mg / time, once or twice a day; Zhibituo tablets (350 mg / tablet, containing approximately 1.3 mg / tablet of monacolin K), with a dosage of 700-1050 mg / time, once or twice a day; Xuezhikang capsules (300 mg / tablet, containing approximately 3.7 mg / tablet of monacolin K), with a dosage of 300-600 mg / time, once or twice a day; natural red yeast rice (containing 0.2% monacolin K), with a dosage of 6 g / time, twice a day. Probucol and red yeast rice were administered simultaneously for an average of 4 weeks. Treatment Results: After patients were treated with different doses of probucol combined with red yeast rice, plasma triglycerides decreased by 34-75% (average values for each treatment group, the same below), with an average decrease of 69% (average values for all patients, the same below); cholesterol decreased by 12-55%, with an average decrease of 43%; and low-density lipoprotein decreased by 18-47%, with an average decrease of 29%. Detailed results are shown in Table B1 below. Table B1 Results of treatment with combination of probucol and red yeast rice Among them: ZZ: probucol 62.5mg + tretinoin 240mg, BID; YY: probucol 125mg + tretinoin 240mg, BID; XX: probucol 125mg + tretinoin 480mg, QD; WW: probucol 312.5mg + tretinoin 240mg, BID; VV: probucol 62.5mg + tretinoin 480mg, BID; UU: probucol 125mg + tretinoin 480mg, BID; TT: Probucol 250 mg + Zhibitai 480 mg, BID; SS: probucol 62.5 mg + Zhibitai 700 mg, BID; RR: probucol 125 mg + Zhibitai 1050 mg, BID; QQ: probucol 125 mg + Xuezhikang 600 mg, BID; PP: probucol 125 mg + natural red yeast rice 6 g, BID; OO: probucol 250 mg + Zhibitai 480 mg, QD (Table B3 and Table B5 also apply). Side effect evaluation: No side effects such as increased muscle enzymes, abnormal liver function, and increased creatinine were observed in all treated patients during the treatment period. Compared to other drugs for treating severe hypertriglyceridemia, the low-dose drug combination of the present invention significantly lowered triglycerides, outperforming fibrates and high-dose fish oil. Furthermore, unlike fibrates and high-dose fish oil, which increase LDL, the drug combination of the present invention also simultaneously lowered cholesterol and LDL-C. See Table B2 below. Table B2 Comparison of the efficacy of the combination of probucol and red yeast rice with other drugs for the treatment of severe hypertriglyceridemia Data sources: a. Liping package insert; b. TriglycerideLoweringDrugs (https: / / pubmed.ncbi.nlm.nih.gov / 28402615 / ). c. ω3 fatty acid ethyl ester 90 soft capsule package insert. Typical case 1: The patient was a 62-year-old female with hypertension, diabetes, hyperlipidemia, and a family history of severe hypertriglyceridemia. Ten years prior, severe hypertriglyceridemia induced pancreatitis, leaving behind diabetic complications. With triglycerides reaching 22.68 mmol / L, cholesterol 9.75 mmol / L, and low-density lipoprotein cholesterol 5.7 mmol / L, she took fenofibrate 0.2 g daily. After 3, 6, and 8 weeks, triglycerides dropped to 6.57 mmol / L, 8.35 mmol / L, and 6.12 mmol / L, respectively. Liver function and muscle enzymes remained stable during this period. After 14 weeks of treatment, creatine kinase was 4402 U / L, myoglobin was greater than 3000 ng / mL, triglycerides were 13.14 mmol / L, aspartate aminotransferase and alanine aminotransferase were elevated, and renal function remained unchanged. After discontinuation of fenofibrate, muscle enzymes returned to normal, but triglycerides remained elevated at 16.58 mmol / L. A trial of statin therapy failed to reduce triglycerides, and muscle enzymes rose again. The statin therapy was discontinued. Because cholesterol was 10.32 mmol / L and probucol had minimal side effects on liver and kidney damage, probucol 0.5 g twice daily was administered. Liver function and muscle enzymes stabilized, but triglycerides remained elevated. However, fibrate and statin therapy could not be continued. During this period, intermittent pain and claudication in both lower limbs gradually progressed to persistent pain and inability to walk. The skin on both lower limbs gradually turned bluish-purple, and the skin temperature increased. Heparin anticoagulation was ineffective. Ultrasound of the lower limb arteries revealed multiple plaques, complete occlusion of most vessels, and severe stenosis in a small number of vessels. Therefore, he received a low-dose red yeast rice and probucol combination treatment, 0.125 grams of probucol and 0.24 grams of Zhibitai each time, twice a day. After 14 days of treatment, triglycerides dropped from 22.02mmol / L to 4.57mmol / L, lower limb pain and cyanosis quickly relieved and disappeared, and he gradually recovered to walk after 1 month. After 4 months of treatment, a B-ultrasound was repeated, and only one artery was completely occluded, and the remaining stenosis was significantly relieved. During the treatment, muscle enzyme and liver function indicators were monitored and stable. Blood lipids were stable at a low level. In the following years, the patient has been receiving red yeast rice and probucol combination treatment, and his liver function gradually returned to normal, muscle enzymes were normal, triglyceride levels fluctuated between 1.5-4mmol / L, no cardiovascular and cerebrovascular events occurred, there was no pain in both lower limbs, both lower limbs had normal activities, and the electrocardiogram QT interval was normal. Surprisingly, it was found that the combination of probucol and red yeast rice had an excellent therapeutic effect on severe hypertriglyceridemia. In particular, when the daily dose of Zhibitai was 480 mg, the therapeutic effect of a daily dose of 125 mg of probucol (2 groups: 62.5 mg of probucol + 240 mg of Zhibitai, BID, and 125 mg of probucol + 480 mg of Zhibitai, QD) was significantly higher than the therapeutic effect of a daily dose of 625 mg of probucol (312.5 mg of probucol + 240 mg of Zhibitai, BID). Example B2: Study on the efficacy of a combination of probucol and red yeast rice in treating hypercholesterolemia Patients: A total of 28 patients with hypercholesterolemia were treated with a combination of probucol and red yeast rice. These patients included 16 males and 12 females, aged 27 to 78 years (mean, 56.54 ± 11.74 years). These patients included those who had previously received statins or a statin combined with a cholesterol absorption inhibitor. These patients also included those with familial hypercholesterolemia and familial severe hypercholesterolemia. Dosage regimen: Probucol is administered orally as commercially available probucol tablets (125 mg / tablet) (can be taken with water or chewed), with a dosage of 62.5-250 mg / time, once or twice a day; red yeast rice is administered orally as the following commercially available Chinese patent medicines (can be taken with water or chewed): Zhibitai capsules (240 mg / tablet, containing approximately 9.1 mg / tablet of monacolin K), with a dosage of 240-480 mg / time, once or twice a day; Xuezhikang tablets (400 mg / tablet, containing approximately 3.7 mg / tablet of monacolin K), with a dosage of 1200-2400 mg / time, once or twice a day; probucol and red yeast rice are administered simultaneously for 7-97 days. Treatment Results: After treatment with different doses of probucol and red yeast rice, patients' plasma cholesterol levels decreased by 40-45%, low-density lipoprotein levels decreased by 45-55%, and plasma triglycerides decreased by 22-49%. Specific results are shown in Table B3 below. Table B3 Treatment results of probucol combined with red yeast rice The dosage regimen is the same as that in Table B1. Side effect evaluation: No side effects such as increased muscle enzymes, abnormal liver function, and increased creatinine were observed in all treated patients during the treatment period. Compared with other drugs for treating hypercholesterolemia: Compared with probucol and red yeast rice used alone at normal doses, the low-dose drug combination of the present invention can significantly reduce cholesterol and low-density lipoprotein-C. Long-term use can reduce cholesterol by 40-45% (calculated as the average value of the values of each dosing group, the same below), and an average of 42% (calculated as the average value of the values of all patients, the same below); low-density lipoprotein-C can be reduced by 45-55% (calculated as the average value of the values of each dosing group, the same below), and an average of 50% (calculated as the average value of the values of all patients, the same below). Plasma triglycerides decreased by 22-49%, an average of 27%, which is significantly greater than the effect of sufficient probucol, Zhibitai and Xuezhikang alone, and is more effective than statins. Although the content of red yeast statin is low, it produces unexpectedly high efficacy when combined with low-dose probucol, which once again shows that low-dose probucol can indirectly expand the dose of statins, producing high efficacy and multiple therapeutic effects. See Table B4 below. Table B4 Comparison of the efficacy of the combination of probucol and red yeast rice with other drugs for the treatment of hypercholesterolemia Data sources: a. Li Jiatai, Clinical Pharmacology (3rd ed.), People's Medical Publishing House, pp. 1530-1531; b. China Heart Alliance, Chinese Expert Consensus on the Clinical Application of Zhibitai Capsules, Chinese Journal of Internal Medicine, 2017, Vol. 56, No. 8, pp. 628-631; c. Lipitor instructions. Example B3: Study on changes in blood lipids after combined treatment (i.e., combined with low-dose probucol) based on the original red yeast rice treatment Treatment subjects: 23 patients with hyperlipidemia who had been taking red yeast rice for more than 8 weeks, 11 males and 12 females, aged 29-77 years. Because their low-density lipoprotein and / or triglyceride levels were not up to standard, they continued treatment with low-dose probucol. Dosing regimen: Probucol is administered orally as commercially available probucol tablets (125 mg / tablet) (which can be taken with water or chewed) at a dose of 62.5-250 mg / dose, one to two times daily. Red yeast rice is administered as Zhibitai capsules (240 mg / capsule, containing approximately 9.1 mg of monacolin K / capsule) at a dose of 240 mg / dose, one to two times daily. Probucol and red yeast rice are taken simultaneously for 7 weeks. Treatment Results: After treatment with varying doses of probucol plus red yeast rice, patients' plasma cholesterol levels decreased by 22-25%, with an average of 24%. Low-density lipoprotein (LDL) levels decreased by 27-34%, with an average of 27%. This further reduction in LDL-C was superior to that achieved with a statin plus ezetimibe (18%-20%). See Table B5 for detailed results. Table B5 Changes in blood lipids after original red yeast rice treatment combined with probucol The dosage regimen is the same as that in Table B1. Example B4: Study on the efficacy of a drug combination of probucol and red yeast rice in treating hypercholesterolemia at double the dose Treatment subjects: Two patients with hypercholesterolemia received probucol and red yeast rice combination therapy, including one male and one female, aged 55-60 years. Dosage regimen: Probucol was administered orally using commercially available probucol tablets (125 mg / tablet) at a dose of 125 or 250 mg twice daily. Red yeast rice was administered using Zhibitai capsules (240 mg / pill, containing approximately 9.1 mg of monacolin K / pill) at a dose of 240 or 480 mg twice daily. Probucol and red yeast rice were administered simultaneously. Initially, the low dose shown in Table B6 was administered for a period of more than 6 weeks, followed by a doubled dose (2 times the original dose) as shown in Table B6 for a period of 5-12 weeks. Table B6 Efficacy of Probucol and Red Yeast Combination at Doubled Dose Results: The results showed that in the treatment of hyperlipidemia, by administering probucol and red yeast rice simultaneously, at a low dose of probucol, when the dose of red yeast rice was doubled, a significant reduction of LDL-C of more than 6% could be achieved. Example B5: Study on the difference between low and high doses of probucol and red yeast rice, taken separately and taken simultaneously Case 1: A 64-year-old female ASCVD patient had cholesterol levels of 5.79 mmol / L, LDL-C of 3.93 mmol / L, and triglycerides of 2.07 mmol / L. The doctor prescribed probucol 125 mg and valproate 0.24 g twice daily. The patient took the prescribed dosage according to the instructions, probucol 500 mg and valproate 0.24 g. Ten weeks later, a follow-up examination revealed cholesterol levels of 4.81 mmol / L, LDL-C of 2.92 mmol / L, and triglycerides of 2.63 mmol / L. The original dosage was resumed, and eight weeks later, the following results were obtained: cholesterol 4.19 mmol / L, LDL-C of 1.99 mmol / L, and triglycerides of 1.87 mmol / L. Results: Comparing the results of the three tests, increasing the dose of probucol in the combination and taking them simultaneously actually reduced the extent of LDL-C reduction, which is contrary to the common sense that the incremental effect of combining two cholesterol-lowering drugs should be enhanced. The therapeutic response of the combination for cholesterol is consistent with its response for severe hypertriglyceridemia. Case 2: A 75-year-old female ASCVD patient had cholesterol levels of 5.73 mmol / L, triglycerides of 1.55 mmol / L, and LDL-C of 3.22 mmol / L. Treatment: The doctor ordered a combined dose of 125 mg of probucol and 0.24 g of ciprofloxacin twice daily. However, the patient insisted that the Chinese and Western medications should be taken separately. After five weeks, a follow-up examination revealed cholesterol levels of 5.74 mmol / L, triglycerides of 1.66 mmol / L, and LDL-C of 3.47 mmol / L. After eight weeks of combined therapy, the results were 3.69 mmol / L, triglycerides of 1.24 mmol / L, and LDL-C of 2.13 mmol / L. Results: Using the same dose of probucol and lipopolysaccharide, we observed differences between separate and simultaneous administration. Separation was ineffective. Increasing the probucol dose, even when taken together, was associated with a weaker LDL-C lowering effect. Despite being commonly used lipid-lowering medications, combined use of red yeast rice and probucol at low doses has not been associated with unexpected benefits. This is due to two factors: first, the customary practice of taking both Chinese and Western medicine separately; second, the common sense principle of increasing the dose for enhanced cholesterol-lowering is to increase the dose. Example B6: Other therapeutic cases of the drug combination of probucol and red yeast rice. Case B1: A 36-year-old male with severe hypertriglyceridemia received probucol 312.5 mg plus 0.24 g of valproate twice daily for three weeks. Case B2: A 67-year-old female with ASCVD received probucol 312.5 mg plus 0.24 g of valproate twice daily for two weeks. The treatment outcomes for Cases B1 and B2 are shown in Table B7. Table B7: Efficacy of combined use of probucol in specific cases In this article, the three indicators of blood lipids, TC, TG and LDL-C, refer to total cholesterol (sometimes also referred to as "cholesterol"), triglycerides, and low-density lipoprotein-cholesterol (sometimes also referred to as "LDL"), respectively. The above embodiments are only used to illustrate the present invention and are not intended to limit the technical solutions described in the present invention. The present invention is not limited to the above specific embodiments. All technical solutions and improvements that do not depart from the spirit and scope of the invention should be considered to fall within the scope of protection of the present invention.

Claims

1. A drug combination, wherein the drug combination is a drug combination comprising probucol and a statin, or a drug combination comprising probucol and red yeast rice; preferably, probucol and the statin or red yeast rice are configured to be administered simultaneously.

2. The pharmaceutical combination according to claim 1, wherein the pharmaceutical combination comprises 20-400 mg of probucol and 0.5-80 mg or 1-80 mg of a statin, for example: 5-80 mg, or 10-80 mg, or 5-40 mg, or 10-20 mg, or 10-40 mg of atorvastatin; or 10-80 mg, or 20-80 mg, or 40-80 mg of fluvastatin; or 5-80 mg, or 10-80 mg, or 10-40 mg, or 20-40 mg, or 10-20 mg of lovastatin; or 0.5-4 mg, or 1-4 mg, or 2-4 mg, or 2-3 mg of pitavastatin; or 5-80 mg, or 10-80 mg, or 20-80 mg, or 20-40 mg, or 10-40 mg, or 10-20 mg of pravastatin; or 2.5-40 mg, or 5-40 mg, or 10-40 mg, or 2.5-20 mg, or 5-10 mg, or 5-20 mg of rosuvastatin; or 5-80 mg, or 20-80 mg, or 5-40 mg, or 20-40 mg, or 10-40 mg of simvastatin.

3. The pharmaceutical combination according to claim 1, wherein the pharmaceutical combination comprises 20-400 mg of probucol and 2-50 mg of red yeast rice, the weight of the red yeast rice being calculated as the active substance monacolin K.

4. The pharmaceutical combination according to any one of claims 1 to 3, characterized in that The form capable of simultaneous administration is an oral unit dosage form selected from tablets, capsules, granules, dripping pills, and micropills, and the oral unit dosage form contains probucol and statins, or probucol and red yeast rice.

5. The pharmaceutical combination according to claim 4, characterized in that The oral unit dosage form such as a tablet is a two-layer or multi-layer oral unit dosage form such as a two-layer or multi-layer tablet, wherein at least one layer contains probucol and a pharmaceutically acceptable carrier thereof, and at least another layer contains a statin or red yeast rice and a pharmaceutically acceptable carrier thereof.

6. The drug combination of any one of claims 1 to 5, for treating hyperlipidemia, treating / preventing atherosclerotic vascular lesions, reducing ischemic stroke, reducing lower limb arteriosclerosis occlusion, reducing ischemic kidney disease, or reducing cardiovascular events in a subject in need thereof; preferably, probucol and a statin or red yeast rice in the drug combination are administered simultaneously.

7. A method for treating hyperlipidemia, treating / preventing atherosclerotic vascular lesions, reducing ischemic stroke, reducing lower limb arteriosclerosis occlusion, reducing ischemic kidney disease, or reducing cardiovascular events in a subject in need thereof, the method comprising administering an effective amount of the drug combination of any one of claims 1 to 5; preferably, probucol and a statin or red yeast rice in the drug combination are administered simultaneously.

8. A pharmaceutical composition for treating hyperlipidemia, treating / preventing atherosclerotic vascular lesions, reducing ischemic stroke, reducing lower limb arteriosclerosis occlusion, reducing ischemic kidney disease, or reducing cardiovascular events, the pharmaceutical composition comprising an effective amount of the drug combination according to any one of claims 1 to 5, and a pharmaceutically acceptable carrier; preferably, probucol and a statin or red yeast rice in the drug combination are administered simultaneously.

9. The pharmaceutical combination according to claim 6, the method according to claim 7, the pharmaceutical composition according to claim 8, characterized in that The amount of probucol (in daily dose) is a / 2b, or 3a / 4b, or 5a / 16b of the maximum daily dose of probucol for cholesterol lowering recommended in the "Guidelines for Chinese Blood Lipid Management (2023)", wherein a and b are integers from 1 to 16, and a≤b; for example, the therapeutically effective amount of probucol is 20-800 mg per day, preferably 20 mg-400 mg; Optionally, when the drug combination is a drug combination comprising probucol and a statin, the amount of the statin (in daily dose) is c / d of the maximum daily dose of statins for lowering cholesterol recommended in the "Guidelines for Blood Lipid Management in China (2023)", wherein c and d are integers of 1-16, and c≤d, for example, c≤d / 2; The maximum daily dose of probucol for lowering cholesterol is 1000 mg; and the maximum daily doses of statins for lowering cholesterol are: lovastatin: 40 mg, pravastatin: 40 mg, simvastatin: 40 mg, fluvastatin: 80 mg, atorvastatin: 80 mg, rosuvastatin: 20 mg, and pitavastatin: 4 mg. Optionally, when the pharmaceutical combination is a pharmaceutical combination comprising probucol and red yeast rice, the amount of red yeast rice (in daily dose) is 2-100 mg, preferably 3-40 mg, 5-35 mg, 7-30 mg, or 7-20 mg, calculated as the active substance monacolin K.

10. The pharmaceutical combination according to claim 6, the method according to claim 7, the pharmaceutical composition according to claim 8, characterized in that The hyperlipidemia meets one of the following requirements (a)-(e): (a) the subject's TG ≥ 5.6 mmol / L, and / or LDL-C > 4.9 mmol / L; (b) the subject's TC>6.22mmol / L, and / or LDL-C>4.14mmol / L, and / or TG>1.7mmol / L; (c) The subject is a patient at very high risk for ASCVD and meets one of the following conditions: (c.1) LDL-C level greater than 1.8 mmol / L; (c.2) The subject has received statin therapy, and / or has received statin or red yeast rice combined with a cholesterol absorption inhibitor, or statin or red yeast rice combined with a PCSK9 monoclonal antibody, or statin or red yeast rice combined with a cholesterol absorption inhibitor and a PCSK9 monoclonal antibody, and the LDL-C level is greater than 1.8 mmol / L; (c.3) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and The subject's LDL-C reduction after treatment is less than 50% compared to baseline; or the subject has severe side effects from statins or red yeast rice and needs to reduce the dosage; or the subject has severe side effects from cholesterol absorption inhibitors or PCSK9 monoclonal antibodies when taking statins or red yeast rice in combination with cholesterol absorption inhibitors or statins or red yeast rice in combination with PCSK9 monoclonal antibodies or statins or red yeast rice in combination with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies and needs to stop taking the drugs; (d) The subject is an ASCVD ultra-high-risk patient and meets one of the following requirements: (d.1) LDL-C level greater than 1.4 mmol / L; (d.2) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and the LDL-C level is greater than 1.4 mmol / L; (d.3) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and The subject's LDL-C level after treatment is reduced by <50% compared to baseline; or Patients who have significant side effects from statins or red yeast rice and need to reduce their dosage; or Patients who have severe side effects from cholesterol absorption inhibitors and / or PCSK9 monoclonal antibodies and need to stop taking statins or red yeast rice in combination with cholesterol absorption inhibitors, or statins or red yeast rice in combination with PCSK9 monoclonal antibodies, or statins or red yeast rice in combination with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies; (e) The subject is a high-risk patient for ASCVD and meets one of the following requirements: (e.1) LDL-C level greater than 2.6 mmol / L; (e.2) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and the LDL-C level is greater than 2.6 mmol / L; (e.3) The subject has received statin or red yeast rice treatment, and / or has received statin or red yeast rice combined with cholesterol absorption inhibitor, statin or red yeast rice combined with PCSK9 monoclonal antibody, or statin or red yeast rice combined with cholesterol absorption inhibitor and PCSK9 monoclonal antibody, and The subject's LDL-C level after treatment is reduced by <50% compared to baseline; or Patients who have significant side effects from statins or red yeast rice and need to reduce their dosage; or Patients who have severe side effects from cholesterol absorption inhibitors and / or PCSK9 monoclonal antibodies and need to stop taking statins or red yeast rice in combination with cholesterol absorption inhibitors, or statins or red yeast rice in combination with PCSK9 monoclonal antibodies, or statins or red yeast rice in combination with cholesterol absorption inhibitors and PCSK9 monoclonal antibodies; The ASCVD extremely high-risk patients, ASCVD ultra-high-risk patients, and ASCVD high-risk patients mentioned therein are divided according to the standards of the "Guidelines for Blood Lipid Management in China (2023)".

11. The pharmaceutical combination according to claim 6, the method according to claim 7, the pharmaceutical composition according to claim 8, characterized in that The hyperlipidemia is (Severe) hypertriglyceridemia, or (Severe) hypercholesterolemia, or A combination of (severe) hypertriglyceridemia and (severe) hypercholesterolemia, or Familial or non-familial (severe) hypertriglyceridemia, or Familial or non-familial (severe) hypercholesterolemia, or A combination of familial or non-familial (severe) hypertriglyceridemia and familial or non-familial (severe) hypercholesterolemia, or Hyperlipidemia that is ineffective or ineffective with statins and / or red yeast rice, or (Severe) hypercholesterolemia that is ineffective or ineffective with statins and / or red yeast rice, or (Severe) hypertriglyceridemia that is ineffective or ineffective with statins and / or red yeast rice, or Hyperlipidemia that is intolerant or unresponsive to fibrates, or (Severe) hypertriglyceridemia intolerant of or unresponsive to fibrates.

12. The pharmaceutical combination according to claim 6, the method according to claim 7, the pharmaceutical composition according to claim 8, characterized in that The therapeutically effective amount of probucol can be 62.5 mg-125 mg, or 62.5 mg-187.5 mg, or 62.5 mg-250 mg, or 62.5 mg-312.5 mg, or 62.5 mg-375 mg, or 50 mg-100 mg, or 50 mg-150 mg, or 50 mg-200 mg, or 50 mg-250 mg, or 50 mg-300 mg, or 50 mg-350 mg, or 50 mg-400 mg per day; When the drug combination is a drug combination comprising probucol and a statin, the therapeutically effective amount of the statin may be: 10-20 mg atorvastatin, 5-10 mg rosuvastatin, 20-40 mg fluvastatin, 5-10 mg simvastatin, 10-20 mg lovastatin, 10-20 mg pravastatin, 0.5-1 mg pitavastatin per day; preferably, 10-20 mg atorvastatin / day; or 5-10 mg rosuvastatin / day; or 10 mg simvastatin / day; or 20 mg fluvastatin / day; or 1 mg pitavastatin / day; Preferably, the drug combination is administered once a day, more preferably, before bedtime; Preferably, the hyperlipidemia is primary hypercholesterolemia.

13. A medicine box, characterized in that The medicine kit has the drug combination according to any one of claims 1 to 5, the amount of probucol and the amount of statin / red yeast rice contained in the medicine kit are as described in claim 2 or 3, and probucol and statin / red yeast rice are provided in the form of a single composition in the medicine kit.

14. A medicine box, characterized in that The medicine kit comprises a medicine combination according to any one of claims 1 to 5, The medicine kit comprises a first pharmaceutical composition containing probucol and a second pharmaceutical composition containing statins / red yeast rice, The first pharmaceutical composition and the second pharmaceutical composition are configured to be administered simultaneously, The amount of probucol in the first pharmaceutical composition and the amount of statin / red yeast rice in the second pharmaceutical composition are as described in any one of claims 2 or 3, The first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form. Preferably, the first pharmaceutical composition and the second pharmaceutical composition are provided in separate dosage forms. More preferably, the separate dosage forms are independently selected from tablets, capsules, granules, pills, and micropills. Alternatively, preferably, the first pharmaceutical composition and the second pharmaceutical composition are provided in a single dosage form. More preferably, the single dosage form is selected from tablets, capsules, granules, pills, and micropills. Further more preferably, the single dosage form such as a tablet is a two-layer or multi-layer oral unit dosage form such as a two-layer or multi-layer tablet, wherein at least one layer contains probucol and a pharmaceutically acceptable carrier thereof, and at least another layer contains red yeast rice and a pharmaceutically acceptable carrier thereof.

15. A medicine box, characterized in that The medicine kit comprises a medicine combination according to any one of claims 1 to 5, The medicine kit comprises one or more identical medicine units isolated from the external environment, each medicine unit comprising a first medicine composition containing probucol and a second medicine composition containing a statin / red yeast rice. The amount of probucol in the first pharmaceutical composition and the amount of statin / red yeast rice in the second pharmaceutical composition are as described in any one of claims 2 or 3, The first pharmaceutical composition and the second pharmaceutical composition are each an oral unit dosage form (i.e., the first pharmaceutical composition and the second pharmaceutical composition are provided in separate unit dosage forms, preferably, the separate unit dosage forms are independently selected from tablets, capsules, granules, pellets, micropills), Opening of each pharmaceutical unit exposes the first pharmaceutical composition and the second pharmaceutical composition to the external environment simultaneously.

16. A kit according to claim 15, characterized in that The medicine box includes one or more identical medicine units isolated from the external environment. One, two, or three medicine units, preferably one or two medicine units, can be opened simultaneously for each administration. Each medicine unit contains probucol and statin / red yeast rice as active ingredients. Opening each medicine unit can expose probucol and statin / red yeast rice to the external environment at the same time.

Images